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ABSTRACT 
 
TARGETING ENERGY METABOLISM IN BRAIN CANCER 
 
Laura M. Shelton 
 
Thesis Advisor: Thomas N. Seyfried 
 
It has long been posited that all cancer cells are dependent on glucose for energy, termed 
the “Warburg Effect”.  As a result of an irreversible injury to the mitochondria, cancer 
cells are less efficient in aerobic respiration.  Therefore, calorie restriction was thought to 
be a natural way to attenuate tumor growth.  Calorie restriction lowers blood glucose, 
while increasing the circulation of ketone bodies.  Ketone bodies are metabolized via 
oxidative phosphorylation in the mitochondria.  Only cells that are metabolically capable 
of aerobic respiration will thus be able to acquire energy from ketone bodies.  To date, 
calorie restriction has been shown to greatly reduce tumor growth and angiogenesis in the 
murine CT2A, EPEN, and human U87 brain tumor models.  Using the novel VM-M3 
model for invasive brain cancer and systemic metastatic cancer, I found that though 
calorie restriction had some efficacy in reducing brain tumor invasion and primary tumor 
size, metastatic spread was unaffected.  Using a bioluminescent-based ATP assay, I 
determined the viability of metastatic mouse VM-M3 tumor cells grown in vitro in serum 
free medium in the presence of glucose alone (25 mM), glutamine alone (4 mM), or in 
glucose + glutamine. The VM-M3 cells could not survive on glucose alone, but could 
survive in glutamine alone indicating an absolute requirement for glutamine in these 
metastatic tumor cells. Glutamine could also maintain viability in the absence of glucose 
and in the presence of the F1 ATPase inhibitor oligomycin.  Glutamine could not 
maintain viability in the presence of the Krebs (TCA) cycle enzyme inhibitor, 3-
nitropropionic acid. The data indicate that glutamine can provide ATP for viability in the 
metastatic VM-M3 cells through Krebs cycle substrate level phosphorylation in the 
absence of energy from either glycolysis or oxidative phosphorylation.  I therefore 
developed a metabolic therapy that targeted both glucose and glutamine metabolism 
using calorie restriction and 6-diazo-5-oxo-L-norleucine (DON), a glutamine analog.  
Primary tumor growth was about 20-fold less in DON treated mice than in untreated 
control mice.  I also found that DON treatment administered alone or in combination with 
CR inhibited metastasis to liver, lung, and kidney as detected by bioluminescence 
imaging and histology.  Although DON treatment alone did not reduce the incidence of 
tumor metastasis to spleen compared to the controls, DON administered together with CR 
significantly reduced the incidence of metastasis to the spleen, indicating a diet/drug 
synergy.  In addition, the phagocytic capabilities of the VM-M3 tumor cells were 
enhanced during times of energy stress.  This allowed for the digestion of engulfed 
material to be used in energy production.  My data provide proof of concept that 
metabolic therapies targeting both glucose and glutamine metabolism can manage 
systemic metastatic cancer.  Additionally, due to the phagocytic properties of the VM-M3 
cell line also seen in a number of human metastatic cancers, I suggest that a unique 
therapy targeting metabolism and phagocytosis will be required for effective management 
of metastatic cancer. 
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 1 
INTRODUCTION   
 
Human brain cancer models 
Glioblastoma multiforme (GBM) is the most common form of adult brain cancer (Wen 
and Kesari 2008).  GBM has a poor outcome due to its invasive and aggressive nature.  
Treatments have been largely ineffective and consist of surgical resection followed by 
radiation and/or chemotherapy (Chang et al. 2005; Wen and Kesari 2008).  Due to the 
invasive nature of GBM, complete surgical removal is not possible.  Many GBMs are 
multicentric, having secondary lesions at sites distant to the primary tumor (Scherer 
1940a; Rubinstein 1972; Laws et al. 1993).  In addition, chemotherapy and radiation are 
toxic, often resulting in further brain damage (Duffner 2006).  In order to develop better 
therapies, reliable animal models are required that focus on the invasive nature of GBM.  
Although a number of brain tumor models exist, none recapitulate all of the 
characteristics of a human GBM, such as the typical growth patterns and infiltrative 
behavior (Szatmari et al. 2006). While xenograft models are attractive, the mouse hosts 
are immune compromised and ignore the effect of an immune-mediated response when 
assessing potential therapies as well as the effects of a native host microenvironment 
(Candolfi et al. 2007; Xie et al. 2008; Huse and Holland 2009).  Additionally, 
xenografted human tumors tend to lose their invasive properties when grown in vivo 
following in vitro culturing (Fomchenko and Holland 2006).  Growth patterns in 
xenografts also do not replicate the growth patterns seen in humans with GBM 
(Fomchenko and Holland 2006; Candolfi et al. 2007; Huse and Holland 2009).   New 
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animal models for GBM are therefore needed that better reflect the properties seen in the 
natural host. 
 
Chemically induced models are grown in immune competent hosts, and to date are some 
of the most commonly used murine syngeneic brain tumor models (Mukherjee et al. 
2002; Mukherjee et al. 2004; Maes et al. 2008).  However, these brain tumors lack glial 
differentiation markers, typical GBM growth patterns, and extensive invasion (Szatmari 
et al. 2006; Maes et al. 2008).  Rat brain tumor models are also available but are highly 
immunogenic thus complicating results of potential therapies (Barth 1998).  There is also 
evidence of spontaneous tumor regression in some rat models of brain cancer (Vince et 
al. 2004).  The rat CNS-1 glioma model is useful for assessing immuno-based therapies 
because it is weakly immunogenic and has greater invasive properties than those seen in 
the more common rat glioma models to include periventricular and perivascular spread 
(Kruse et al. 1994).  The leptomeningeal spread however, could also be a result of the 
inoculation method (Kruse et al. 1994).  In general, the invasive properties of most rodent 
models are limited to within the area of the main tumor mass (Candolfi et al. 2007; 
Zagzag et al. 2008).  Hence, none of the currently available rodent brain tumor models 
reflect the growth characteristics of human GBM.   
 
 
Due to the limitations of current brain tumor models, transgenic models have been 
developed based on gain of function or targeted deletions in glioma-associated genes 
(Holland 2001).  Complicated breeding and genotyping procedures however are required 
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to generate these transgenic models (Dai and Holland 2001; Holland 2001; Hu and 
Holland 2005).  Though these transgenic models often replicate high-grade gliomas, a 
model with a mutation in a single pathway is not a realistic representation of the human 
disease because human gliomas contain a number of distinct genetic abnormalities (Louis 
2006; Parsons et al. 2008; Huse and Holland 2009).   Also, the tumors that develop are 
not always identical in morph or grade (Huse and Holland 2009).  As an alternative, 
MMLV (moloney murine leukemia virus)-based somatic gene-transfer glioma models 
rely on retroviral infection of glial cells (Dai and Holland 2001; Assanah et al. 2006).  
This method allows for the delivery of multiple genes thus bypassing the production of 
additional transgenic lines (Huse and Holland 2009).  However, retroviral infection is 
often non-specific, targeting numerous cells and resulting in heterogeneous tumors of 
unknown origin (Dai and Holland 2001; Hu and Holland 2005). 
 
In addition to the available rodent models, a number of dog breeds are predisposed to 
spontaneous brain tumors to include boxers and golden retrievers (Heidner et al. 1991; 
LeCouteur 1999).  Some of these brain tumors are highly invasive and closely resemble 
the histological and growth characteristics of human GBM (Lipsitz et al. 2003; Candolfi 
et al. 2007).  However, dog models are not readily available and researchers would need 
to rely on the recruitment of recently diagnosed dogs for studies (Candolfi et al. 2007).  
The specific grade and type of dog glioma also varies and only about 5% of all dog brain 
tumors are GBM (Foster et al. 1988; Lipsitz et al. 2003). 
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The VM-M3 tumor is unique in that it arose spontaneously in the brain of the VM mouse 
strain.  The VM strain is known to have a relatively high incidence (1.5%) of 
spontaneous brain tumors most of which are described histologically as astrocytomas 
(Fraser 1971, 1986a).  The VM-M3 brain tumor expresses multiple properties of 
microglia similar to that seen in numerous other types of invasive/metastatic cancers of 
neural and non-neural origin (Huysentruyt et al. 2008; Huysentruyt et al. 2010).  In 
addition, the VM-M3 tumor cells highly express the chemokine receptor CXCR4, whose 
expression has been linked to the degree of malignancy of human gliomas and has been 
found to play a major role in tumor cell migration (Bian et al. 2007; Ehtesham et al. 
2008; Huysentruyt et al. 2008; Stevenson et al. 2008; Zagzag et al. 2008).  High CXCR4 
levels are more often associated with the higher-grade gliomas, including GBM and 
indicate a poor postoperative prognosis (Bian et al. 2007).  The VM-M3 tumor is highly 
invasive when implanted orthotopically and invading tumor cells can be found deep 
within the brain parenchyma. These tumors are weakly immunogenic and can be grown 
in the syngeneic VM mouse host with predictable and reproducible growth rates and 
patterns (Huysentruyt et al. 2008; Huysentruyt et al. 2010).   In addition, the VM-M3 
tumors are labeled with the firefly luciferase gene allowing for non-invasive detection of 
tumor growth via bioluminescent imaging (Huysentruyt et al. 2008; Huysentruyt et al. 
2010).  Bioluminescent imaging has been developed for a number of glioma tumor model 
systems and is established as an accurate measurement of tumor growth over time 
(Deroose et al. 2006; Szentirmai et al. 2006; Maes et al. 2008).   Therefore, the VM-M3 
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tumor manifests several of the characteristics seen in aggressive malignant gliomas to 
include GBM. 
 
Tumor metabolism 
Over 70 years ago, Otto Warburg theorized that all cancer cells are heavily dependent on 
glycolysis, which was later termed “The Warburg Effect”.  This theory was based on 
metabolic studies in a large number of carcinomas, including lung, colon, skin, and 
larynx (Warburg 1931).  A high rate of glycolysis was found in tumors with low oxygen 
uptake.  The release of lactic acid was correspondingly high in the carcinomas even in the 
presence of oxygen, thus suggesting that all tumor cells suffered from a disturbance of 
respiration. A mitochondrial dysfunction was thought to be the cause of the respiration 
impairment and hence the “origin of cancer cells” (Warburg 1956). As a result, tumor 
cells were thought to be strictly reliant on glucose for energy.  Therefore, exploiting 
abnormal brain tumor metabolism is an attractive therapeutic target.  Under normal 
physiological conditions brain cells acquire most, if not all of their energy from glucose 
(Seyfried and Mukherjee 2005a).  However, under conditions of fasting or low blood 
glucose, normal tissue as well as the brain is capable of utilizing ketone bodies for energy 
(Owen et al. 1967; Cahill 1970; VanItallie and Nufert 2003; Morris 2005).  -
hydroxybutyrate is the main blood ketone that is capable of crossing the blood brain 
barrier through the monocarboxylic acid transporters (MCTs) (Koehler-Stec et al. 1998; 
Pellerin et al. 2005).  Although astroctyes are highly glycolytic in cell culture, they 
maintain the capabilities to perform oxidative phosphorylation.  It has been shown that 
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astrocytes will shift to fatty acid oxidation during glucose withdrawal (Jelluma et al. 
2006).  An impaired respiration would prevent tumors from utilizing ketones as an energy 
source because ketones are oxidized to acetyl Co-A and directly enter the TCA 
(VanItallie and Nufert 2003). Hence, a diet therapy based on reducing glucose levels 
while maintaining high ketone levels may prove effective in the treatment of cancers that 
rely on glycolysis (Magee et al. 1979; Mukherjee et al. 2002; Mukherjee et al. 2004; 
Zhou et al. 2007).  
 
Calorie Restriction 
Cancer cells frequently exhibit increased glycolysis and therapies that target glucose 
metabolism have been exploited in the past to include 2-deoxyglucose (2-DG) and calorie 
restriction (CR) (Mukherjee et al. 2002; Mukherjee et al. 2004; Marsh et al. 2008a).  
Calorie restriction is a powerful anti-angiogenic therapy that also reduces tumor growth 
in various mouse and human xenograft models of brain cancer (Mukherjee et al. 2002; 
Mukherjee et al. 2004; Marsh et al. 2008a).  In addition, calorie restriction has been 
shown to target Akt signaling pathways involved in the antiapoptotic and glycolytic 
phenotype of some tumors (Marsh et al. 2008b).  Calorie restriction is an effective tool 
for reducing circulating blood glucose, thereby limiting this energy source to the tumor 
cells.  Calorie restriction also acts by elevating ketone bodies due to the lowered blood 
glucose levels, which as previously stated, can be metabolized by oxidative 
phosphorylation in normal healthy cells (Seyfried and Mukherjee 2005a).  Because tumor 
cells have an impaired respiration, ketone bodies cannot be used as an energy substrate. 
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In addition, calorie restriction reduces the production of free radicals and thus reduces 
inflammation (Veech 2004; Seyfried and Mukherjee 2005b). Evidence has since 
confirmed that high blood glucose levels act as an accurate biometric predictor of poor 
survival in humans with Glioblastoma multiforme (McGirt et al. 2008; Derr et al. 2009).  
To date, the effect of calorie restriction has not been tested on invasive brain cancer in 
mice. 
 
Role of Glutamine 
In recent years a focus has shifted to the role glutamine plays in the growth of cancer 
cells.  It has long been known that glutamine is essential for rapidly dividing cells, cells 
of myeloid origin, fibroblasts in culture, and cancer cells (Zielke et al. 1976; McKeehan 
1982; Kovacevic and McGivan 1983; Newsholme et al. 1985; Newsholme et al. 1987; 
Baggetto 1992; Medina 2001; Yuneva 2008).   Tumors have been termed “glutamine 
traps,” consistent with their ability to take in exceedingly large amounts of glutamine 
relative to the rest of the body (Souba 1993; Medina 2001).   In addition to enhanced 
expression of glutamine transporters, enzyme activities such as glutaminase, which are 
involved in glutamine metabolism, are elevated in a number of tumors (Board et al. 1990; 
Perez-Gomez et al. 2005).  Evidence has shown a correlation between enhanced tumor 
glutaminase activity and enhanced malignancy (Souba 1993; Medina 2001).  Glutamine 
was believed to play a role in macromolecular synthesis particularly of purines and 
pyrimidines and as a precursor in anapleurotic reactions (DeBerardinis et al. 2007; 
DeBerardinis 2008; Deberardinis et al. 2008).  In this capacity, it was thought that 
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glutamine was converted to pyruvate via mitochondrial malate and ultimately to lactic 
acid.  This would regenerate NADPH to be used in the pentose phosphate pathway and 
fatty acid synthesis (DeBerardinis et al. 2007; DeBerardinis 2008).   However, it was 
determined that glutamine intake far exceeded macromolecular synthesis and instead was 
used as an energy substrate (Reitzer et al. 1979; DeBerardinis et al. 2007; Matheson et al. 
2007).  Evidence has indeed shown that glutamine, not glucose, is the major source of 
energy for HeLa cells (Reitzer et al. 1979).  However, there is debate as to the origin of 
this ATP, as cancer cells frequently exhibit mitochondrial respiratory impairments 
(Warburg 1956; Kiebish et al. 2008a; Ortega et al. 2009). 
 
Glutamine is capable of entering a truncated TCA cycle whereby it can be converted back 
to pyruvate via malate.  However, this could occur either at the expense of TCA malate as 
well as at the expense of extramitochondrial malate (See Supplemental Figures 3 and 4).   
The first possibility is that TCA malate exits the mitochondria and is converted to 
pyruvate via cytosolic malic enzyme (Newsholme et al. 2003b; DeBerardinis et al. 2007; 
Deberardinis et al. 2008).   In addition, citrate is capable of exiting the mitochondria 
resulting in the production of extramitochondrial malate (Sauer and Dauchy 1978; 
McKeehan 1982; Moreadith and Lehninger 1984; Baggetto 1992; Teller et al. 1992).  
Extramitochondrial malate is derived from citrate via the sequential action of ATP citrate 
lyase and malate dehydrogenase.  This takes place in the cytoplasm where citrate from 
the TCA is used to generate acetyl-CoA for fatty acid synthesis (Baggetto 1992; Board 
and Newsholme 1996).  Extramitochondrial malate re-enters the mitochondria where 
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mitochondrial malic enzyme regenerates pyruvate (Kovacevic and McGivan 1983; 
Moreadith and Lehninger 1984), thus allowing acetyl-CoA to continually feed into the 
TCA.  This could potentially allow for the continual generation of ATP via substrate 
level phosphorylation in the TCA in the absence of oxidative phosphorylation.  In the 
same manner, cytosolic pyruvate derived from mitochondrial malate is capable of re-
entering the TCA as acetyl-CoA.   However, DeBeradinis et al. demonstrated that 
glutamine derived pyruvate generated from TCA malate is more frequently converted to 
lactic acid (DeBerardinis et al. 2007).   Therefore, it is unclear whether glutamine 
primarily plays an active role in macromolecular synthesis and anapleurosis or whether it 
can also serve as an energy generating substrate. 
 
Currently, there are a number of drug targets of glutamine metabolism to include 
phenylbutyrate (PBA), and the glutamine analogs acivicin and 6-diazo-5-oxo-L-
norleucine (DON) (Livingston et al. 1970; Darmaun et al. 1998).  PBA has been used 
extensively in vitro and in human trials as a histone deacetylase inhibitor (Engelhard et 
al. 1998; Dyer et al. 2002; Li et al. 2004; Lopez et al. 2007).  In the body, PBA is 
metabolized to phenylacetate (PA) by -oxidation (Darmaun et al. 1998).  PA then 
covalently conjugates with glutamine via phenylacetyl-CoA ligase and acyl-CoA-L-
glutamine N-acyl-transferase (Darmaun et al. 1998).  This glutamine-PA conjugate is 
then excreted, effectively reducing the amount of free glutamine available to the tumor 
cells.  The glutamine analogs have also shown promising results in vitro and in murine 
models of cancer (Rabinovitz et al. 1959; Ovejera et al. 1979; Lyons et al. 1990; Griffiths 
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et al. 1993).  However, limited success has been achieved with PBA, and high toxicities 
of the glutamine analogs limit their use for human studies (Magill et al. 1957; Livingston 
et al. 1970; Griffiths et al. 1993; Phuphanich et al. 2005)  
 
Macrophage properties of metastatic cancers 
Recent evidence indicates that metastatic cancers display multiple properties of 
macrophages.  In particular, phagocytosis appears to be an important mechanism 
employed by metastatic cancer cells (Fais 2007).   Metastatic breast cancer cells were 
found to internalize fluorescent Matrigel, latex beads, and yeast (Montcourrier et al. 
1994; Coopman et al. 1996; Coopman et al. 1998; Ghoneum and Gollapudi 2004).  This 
phagocytic capacity was observed among the more aggressive and invasive cell lines 
studied (Montcourrier et al. 1994).  In addition, tumor phagocytosis of erythrocytes as 
well as other tumor cells was found in a patient with a cerebellar medulloblastoma 
(Youness et al. 1980).  However, this mechanism seems to function particularly when the 
tumor cells have become nutrient stressed (Fais 2007).  Metastatic melanoma cells were 
shown to survive on human T-lymphocytes when stressed by a reduction of nutrients 
(Lugini et al. 2006).  This perhaps allows the tumor cells to avoid autophagy, which is a 
self-destructive process (Fais 2007).  Therefore, phagocytosis could perhaps become a 
novel target of anticancer therapies, particularly for the invasive and metastatic cancers. 
 
Currently, a few reports have suggested potential anti-cancer effects of cholorquine (CQ), 
a traditional anti-malarial compound (Zeilhofer et al. 1989; Briceno et al. 2007; Maclean 
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et al. 2008).  Specifically, CQ targets to the lysosomes, raising intra-lysosomal pH (Pless 
and Wellner 1996).  As a result, lysosomal digestive enzymes are rendered inactive 
(Fredericksen et al. 2002).  Chloroquine is thought to exert its effect by inhibiting the 
autophagy pathway (Dang 2008; Maclean et al. 2008).  Also termed “self-eating”, this 
pathway allows for the digestion of internal organelles during times of nutrient 
deprivation (Fais 2007; Dang 2008).  However, inhibiting the digestion of phagocytosed 
extracellular material would represent a novel use for chloroquine.  The therapeutic 
effects of choloquine should be at a maximum when the tumor cells are stimulated to 
phagocytose.  If nutrient deprivation is a phagocytic trigger, then calorie restriction 
combined with chloroquine could exert a significant amount of stress on the tumor cells, 
resulting in cell death. 
 
The VM-M3 cell line has a number of myeloid properties to include morphology, gene 
expression, lipid profile, and phagocytic capacity (Huysentruyt et al. 2008). This tumor 
arose spontaneously in the brain of a VM mouse and has multiple properties of 
Glioblastoma multiforme to include systemic metastasis (Ng et al. 2005).  While 
metastasis is not commonly seen in gliomas, GBM is highly metastatic once the tumor 
cells reach the blood stream (Rubinstein 1972; Youness et al. 1980; Hoffman and Duffner 
1985; Taha et al. 2005; Kauffman et al. 2007).  From a subcutaneous implantation site, 
the VM-M3 tumor recapitulates all the major hallmarks of metastasis, to include 
detachment from the primary tumor, intravasation into the blood stream, evasion of 
immune attack, extravasation at a distant capillary bed, and growth at distant sites 
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(Chambers et al. 2002; Bacac and Stamenkovic 2008; Huysentruyt et al. 2008; 
Huysentruyt et al. 2010).  In addition, this tumor has multiple properties of myeloid cells 
also seen in a number of human metastatic cancers to include lung, breast, colon, and skin 
(Spivak 1973; Abodief et al. 2006; Lugini et al. 2006; Fais 2007; Huysentruyt et al. 2008; 
Moonda and Fatteh 2009; Huysentruyt et al. 2010).  It has been established as a model for 
both the study of invasive brain cancer and systemic metastatic cancer (Huysentruyt et al. 
2008; Huysentruyt et al. 2010).   Therefore, the VM-M3 model is a valuable tool for the 
pre-clinical evaluation of potential anti-invasive and anti-metastatic therapies. 
 
I hypothesized that due to the myeloid origin of the VM-M3 cell line, these tumor cells 
are highly dependent on glutamine for energy and survival.  In addition, I hypothesized 
that phagocytosis may play a role in the survival of the VM-M3 cell line during energy 
stress.  Therefore, I suggest that a diet/drug combination that specifically targets glucose, 
glutamine and phagocytosis is required to manage VM-M3 metastatic and invasive 
cancer.  Due to the similar properties of the VM-M3 cell line to various other human 
metastatic tumors, I also suggest that the management of human metastatic cancer will 
rely on a similar therapeutic combination. 
 13
MATERIALS AND METHODS 
 
 
Cell Lines  
Tumor cell lines were prepared as described previously (Huysentruyt et al. 2008; 
Huysentruyt et al. 2010).  Briefly, tumor tissue was removed from the mice and was 
transferred to a Petri dish containing Dulbecco’s Modified Eagle medium (DMEM, 
Sigma, St. Louis, MO) with high glucose (25 mM) supplemented with 10% fetal bovine 
serum (FBS, Sigma) and 50 μg/ml penicillin-streptomycin (Sigma).   The tumor tissue 
was minced thoroughly to obtain a cell suspension.  1 ml of the cell suspension was then 
seeded into a tissue culture flask containing DMEM (25mM glucose, 10%FBS).  The VM 
tumor cells were evaluated after a minimum of eight passages to insure that the cells lines 
were uniformly homogeneous.  The astrocyte C8-D30 (Astrocyte type III clone, AC) was 
purchased from American Type Culture Collection (Manassas, VA).   The mouse 
astrocytoma CT-2A cell line was generated from the chemically induced tumor as 
previously described (Seyfried et al. 1992). 
 
Cell Culture Conditions 
The cell lines were grown in cell culture flasks (Corning, Inc., Corning, NY) in Dulbecco’s 
Modified Eagle medium (DMEM, Sigma, St. Louis, MO) with high glucose (25 mM) 
supplemented with 10% fetal bovine serum (FBS, Sigma) and 50 μg/ml penicillin-streptomycin 
(Sigma) (complete DMEM). The cells were cultured in a CO2 incubator with a humidified 
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atmosphere containing 95% air and 5% CO2 at 37°C. At confluency, cells were removed from 
the flasks with a cell scraper and were passed to a new culture flask.   
 
Transduction of Cell Lines 
Transduction was performed as previously described (Huysentruyt et al. 2008).  Briefly, 
the lentiviral vector CSCGW2-Fluc-IG was derived from CSCGW by deleting all 
promoter elements from the U3 region in the 3'LTR and inserting a firefly luciferase 
(Fluc)-IRES-EGFP cassette under control of the CMV promoter (gift from Miguel Sena-
Esteves). Lentiviral vector stocks were produced with titers of 1x10
8
 tu/mL.  One day 
prior to infection, approximately 100,000 cells were plated in a 6-well plate in DMEM.  
Infection was performed with a multiplicity of infection (MOI) of 100 in a total volume 
of 1.5 ml of DMEM.  After 24 hr of incubation, 2.0 ml of fresh medium was added to the 
well.  To obtain a clonal cell line, we passaged the cells 3 times and then sorted them into 
a 96-well plate based on EGFP expression using a MoFlo cell sorter (Dako, Carpinteria, 
CA). 
 
ATP and VM-M3 cell number curve 
For the ATP curve, varying concentrations of ATP were diluted in culture media and 
added to a 24 well plate.  Both luciferase and luciferin were added and the plate was 
imaged for approximately 5 minutes on the Xenogen IVIS System as described below.  
For the cell number curve, varying cell numbers were seeded in culture media in a 24 
well plate.  The cells were then imaged on the Xenogen IVIS System for approximately 5 
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minutes. 
 
Experimental Medias 
DMEM powder (Sigma) was prepared as directed without the addition of glucose, 
glutamine or FBS.  The pH of this media was adjusted to 7.4.  This “minimal” media was 
then sterile filtered, supplemented with 50 μg/ml penicillin-streptomycin (Sigma) and 
stored at 4°C.  Using this minimal media as a base, all other experimental medias were 
prepared.  The pH of each experimental media was re-adjusted to 7.4 and was sterile 
filtered.  Experimental medias include 25 mM glucose + 4 mM glutamine, 25 mM 
glucose (Sigma), 4 mM glutamine (Sigma), 4 mM glutamine + 1 mM hepanoic acid 
(Sigma), 25 mM glucose or 4 mM glutamine + 10mM -hydroxybutyrate (Sigma), and 
various combinations of glucose and glutamine concentrations. 
 
Metabolic Profiling  
Approximately 5 x 10
4
 cells were seeded into two 24 well plates in complete DMEM.  
300 μg/ml of D-luciferin was added to the wells of one plate and the cells were imaged 
immediately on the Xenogen IVIS system for 3-5 minutes (Xenogen, Hopkington, MA) 
to record the bioluminescent signal from the cells.  This reading was recorded as the 0 hr 
time point. After imaging, the cells were allowed to settle for 6-9 hrs before being rinsed 
with minimal media and incubated in the various experimental medias.  For select 
experiments, these medias also contained various drugs to include 3 mM meso-Tartrate 
(Sigma), 2 mM 3-Nitropropionic acid (3NP, Sigma) and 175 μM Diadenosine 
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Pentaphosphate (Ap5A, Sigma).  24 hrs later the cells were imaged again on the Xenogen 
IVIS system for 3-5 minutes.  The data is represented as the percent survival relative to 
the 0 hr time point.  For select experiments, media aliquots were taken at each time point 
for lactate measurements.  A drug toxicity curve was initially generated for all metabolic 
inhibitors as described below.  The inhibitor dose chosen for each experiment yielded an 
approximate 40% reduction in cell number relative to the non-drug control.  At this 
concentration, the inhibitor in complete media reduced cell growth but did not result in 
any cell death.  This concentration was chosen in an effort to avoid potential non-specific 
toxicities. 
 
Drug Toxicity Curves 
Approximately 1 x 10
5
 cells were seeded in 24-well plates and allowed to settle for 24 
hrs.  After 24 hrs some wells were imaged to obtain a 0 hr initial bioluminescent signal.  
The wells were then rinsed with minimal media and incubated in complete media plus the 
various drug concentrations (Sodium Phenybutyrate (PBA), Scandinavian Formulas, 
Sellersville, PA, 6-Diazo-5-oxo-L-norleucine (DON), Sigma).  All drug stocks were 
prepared in complete media and sterile filtered.  After a 24 hr incubation in the various 
drug medias, the cells were imaged for 3-5 minutes on the Xenogen IVIS system 
(Xenogen, Hopkington, MA) to record the bioluminescent signal from the cells.   For 
extended experiments, the wells were incubated in fresh media + drug and incubated for 
an additional 24 hrs.  Data is represented as the percent survival relative to the non-drug 
control at 24 hrs or as the percent survival relative to a 0 hr time point over 48 hrs. 
 17
 
Oligomycin Sensitivity 
Approximately 1 x 10
5
 VM-M3 or CT-2A cells were seeded in 24 well plates and 
allowed to settle for 24 hrs.  After 24 hrs, the wells were rinsed with minimal media and 
incubated in various medias containing 5 ug/ul oligomycin (Sigma).  An initial reading 
on the Xenogen IVIS system was obtained prior to the addition of oligomycin.  The cells 
were incubated in the medias containing oligomycin over 2 hrs and then imaged again on 
the Xenogen imaging system.  Media aliquots from the CT-2A experiment were taken for 
lactate measurements. 
 
Matrigel Phagocytosis Assay  
Approximately 5 x 10
5
 cells were added to 200 μL growth factor reduced Matrigel 
Matrix (BD Biosciences) in a 1:2 ratio (v:v).  The cell/matrix mixture was then divided 
among 6 wells of a 24 well plate.  Additional wells were seeded for the 0 hr time point.  
The matrix was allowed to solidify at room temperature for 20 minutes before the 
addition of complete DMEM.  Non-matrigel wells were seeded with approximately 8.3 x 
10
4 
cells.  The cells with or without Matrigel were imaged on the Xenogen IVIS system 
(Xenogen, Hopkington, MA) to record the bioluminescent signal.  This reading is 
recorded as the 0 hr time point. After imaging the cells were allowed to settle for 6-9 hrs 
in complete DMEM before being rinsed with minimal media and incubated in 5 mM 
glucose (VM-M3) or 0.8 mM glutamine (CT-2A) ± 20 μM chloroquine.  The plate was 
then imaged again at 24 hrs.  The data is represented as the percent survival relative to the 
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0 hr time point.  Media aliquots were taken for lactate determinations.   
 
Latex Bead Phagocytosis assay  
Cell phagocytic capacity was determined by using a modification of a standard 
fluorometric assay (Oda and Maeda 1986).  Fluoresbrite® YG carboxylate microspheres 
(1 μm diameter, Polysciences, Warrington, PA) were prepared in a gly-NaOH buffer as 
described below. Cells were seeded in 2-well Lab-Tek Chambered Coverglass Systems 
(Nunc, Rochester, NY) and were allowed to adhere in DMEM. The cells were then 
incubated with the beads for 1 hr and were rinsed with DMEM to remove excess beads. 
Phagocytosis of beads was detected by confocal microscopy (Leica DMI6000 inverted 
scope equipped with the Leica TCSSP5 confocal system, Wetzlar, Germany) and the 
cells were photographed using Lecia software. 
 
Collagen Coated Latex Bead Phagocytosis Assay   
Latex beads (Polysciences) were prepared as previously described (Naidu et al. 1988; 
Castellanos et al. 2000).  Briefly 250 μL of beads were mixed with 750 μL gly-NaOH 
buffer (pH 8.2).  This mixture was centrifuged for 5 min at 4500 x g.  The bead pellet was 
then resuspended in 750 μL of fresh gly-Na0H buffer.  This suspension was divided into 
4 aliquots.  The aliquots were incubated in the presence or absence 0.5 μg/μL of type VI 
collagen (Sigma) for 12 hrs at 30 °C on at horizontal shaker at 50 rpm.  After 12 hrs the 
mixture was centrifuged for 5 min at 9200 x g at room temperature.  The pellet was 
resuspended in 1 mL of PBS and stored at 4°C.  For the cell assay, approximately 1 x 105 
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VM-M3 cells were seeded in 24 well plates. The cells were imaged on the Xenogen IVIS 
system (Xenogen, Hopkington, MA) to record the bioluminescent signal from the cells.  
This reading is recorded as the 0 hr time point. After imaging, the cells were allowed to 
settle for 6-9 hrs before being rinsed with minimal media and incubated in minimal media 
+ 5 mM glucose with coated or non-coated latex beads.  The plate was then imaged again 
24 hrs later.  The data is represented as the percent survival relative to the 0 hr time point.  
Media aliquots were taken for lactate and ammonia measurements. 
 
Ketone Transition 
Approximately 5 x 10
4
 Astrocyte and VM-M3 cells were seeded into 24 well plates in 
complete media.  Cells were allowed to settle for 6 hrs and the media was changed to 
12.5 mM glucose, 2 mM glutamine ± 10 mM -hydroxybutyrate (-OHB, Sigma) for 48 
hrs.  After 48 hrs the cells were incubated in media that was diluted 1:1 with minimal 
media ± 10 mM -OHB.  After 24 hrs, the media was again diluted 1:1 with minimal 
media ± 10 mM -OHB.  After each 24 hr incubation the media was serially diluted until 
a final concentration of 0.39 mM glucose, 0.0625 mM glutamine ± 10 mM -OHB.  The 
cells were then incubated in 0 mM glucose, 0 mM glutamine ± 10 mM -OHB for 24 hrs.  
The cells were then incubated in complete DMEM ± 10 mM -OHB until the cells began 
to divide again.  At this point, all VM-M3 cells had died, while the astrocytes began to 
divide.  After a new population of cells was established, the astrocytes were transitioned 
again off of DMEM down to 0.39 mM glucose, 0.0625 mM glutamine ± 10 mM -OHB.  
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Once a stable population was established cells were maintained in 3 mM glucose, 0.5 
mM glutamine, and 10 mM -OHB. 
 
Ketone Determination 
The ketone body -hydroxybutyrate (-OHB) was measured enzymatically in plasma or 
serum with a modification of the Williamson et al. procedure (Williamson et al. 1962). 
 
Lactate Determination 
Lactate was determined using the Lactate Assay Kit from the Biomedical Research 
Service Center at the University of Buffalo, NY.  
 
Ammonia Determination  
Ammonia was determined using an ammonia/glutamine Assay Kit from Megazyme 
(Bray, Ireland). 
 
Proton NMR  
VM-M3 cells were grown to approximately 80% confluency under normal culture 
conditions.  The cells were then incubated in either 25 mM glucose + 4 mM glutamine, 
25 mM glucose, or 4 mM glutamine for 12-24 hrs.  Media aliquots were lyophilized and 
stored at -80°C until the time of analysis.  Adherent cells were scraped and rinsed in PBS 
for a total of 3 times.  They were spun down and lysed in 0.5 mL cold 70% ethanol.  The 
lysate was then bath sonicated for 10 minutes and spun down for 5 min at 4,000 r.p.m.  
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The supernatant was collected and the resulting pellet was washed again in 70% ethanol 
for a total of 4 times.  The resulting supernatant was frozen at -80°C and lyophilized.  For 
13
C labeling experiments, the cells were incubated in either [U]
 13
C glutamine 
(Cambridge Isotope Laboratories, Inc, Andover, MA) or  [U]
 13
C glutamine + unlabeled 
25 mM glucose for 12 hrs and the cell lysates and media were collected as described 
above. 
 
Mice 
Mice of the VM/Dk (VM) strain were obtained as gifts from G. Carlson (McLaughlin 
Research Institute, Great Falls, Montana) and from H. Fraser (University of Edinburgh, 
Scotland).  All Mice used in this study were housed and bred in the Boston College 
Animal Care Facility using husbandry conditions as previously described (Ranes et al. 
2001).  All animal procedures were in strict accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Institutional Animal Care 
Committee. 
 
Origin of VM tumors 
The VM-NM1 and the VM-M3 tumors arose spontaneously in the cerebrum of adult VM mice as 
described previously (Huysentruyt et al. 2008).  The tumors were detected during routine 
examination of the VM mouse colony over a period of several years (1993-2000).  The tumors 
were grossly identified in the cerebrum as poorly defined masses (about 3 x 1 x 1 mm) similar to 
those described previously for other spontaneous tumors in the VM mouse brain (Fraser 1986b; 
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El-Abbadi et al. 2001).  In order to preserve in vivo viability, each tumor was immediately 
resected and implanted intracerebrally (i.c.) into host VM mice as described below.  As soon as 
cranial domes appeared, the tumors were passaged again into several host VM mice.  After a 
total of three i.c. passages, the tumors were grown subcutaneously (s.c.) and cell lines were 
prepared from each tumor as described above.  All cell lines were cultured under identical 
conditions to reduce environmental variability. 
 
Intracranial Implants  
Tumor implantation was performed as previously described (Ranes et al. 2001).  Briefly 
mice are anaesthetized with Avertin (0.1mL/10g).  The tops of the heads are disinfected 
with ethanol and a small incision is made in the scalp of the mouse over the midline.  A 
3mm
3
 burr hole is made in the skull over the right parietal region behind the coronal 
suture and lateral to the sagital suture.  Using a trocar, a small (1mm
3
) tumor fragment is 
implanted into the hole made in the skull.  The flaps of skin are then immediately closed 
with collodion.  Additionally, some implants were performed using approximately 1-2 x 
10
4
 cells in 5μL PBS.  The cells were injected into the right cerebral hemisphere using a 
Hamilton syringe.  All tumor-implanted mice reached morbidity at approximately 12-15 
days regardless of implant method.  Both methods result in the implantation of tumor 
fragments or tumor cells approximately 1.5-2 mm deep into the cortical region as 
previously described (Shapiro et al. 1970).  Tumor cells are also highly invasive 
regardless of implant method.  The mice were placed in a warm room (37°C) until they 
were fully recovered.  
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Subcutaneous Implants 
For s.c. implantation, VM mice were anaesthetized with Isoflurane (Halocarbon, River 
Edge, NJ), and the tumor was implanted by a s.c. injection of 0.1 ml of small tumor 
pieces suspended in 0.2 ml PBS by use of a 1 cc tuberculin syringe attached to an 18-
gauge needle into the right flank.  All mice recovered from their surgical procedure and 
were returned to their cages when they became fully active. 
 
Bioluminescent Imaging  
The Xenogen IVIS system (Xenogen, Hopkington, MA) was used to record the 
bioluminescent signal from the luciferase labeled tumors as described previously 
(Huysentruyt et al. 2008). For in vivo imaging, mice received an intraperitoneal injection 
of D-Lucifierin (50 mg/kg, Xenogen) and Avertin (0.1 mL/10g).  Imaging times ranged 
from 30 sec to 15 min, depending on the time point.  For ex vivo imaging, organs were 
entirely removed and rinsed in PBS.  Organs were imaged in 300 μg/ml D-luciferin in 
PBS from 1-6 min.   For i.c. studies, brains were removed and split down the midline.  
Individual hemispheres were imaged separately in 300 μg/ml D-luciferin in PBS, and 
imaged from 1-15 min.  For the analysis of distal tumor spread, each hemisphere was 
further dissected into the cerebellum, brain stem, cortex, and hippocampus and imaged in 
an additional 300 μg/ml D-luciferin in PBS.  Right and left hemisphere brain regions 
were imaged separately. 
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Dietary/Drug Regimens, Body Weight, and Food Intake Measurements  
Adult male and female VM mice of approximately 60-90 days old were separated into individual 
housing 1-2 days before tumor implantation.  Individually housed mice were kept in plastic 
cages with filter tops containing Sani-Chip bedding (P.J. Murphy Forest Products Corp., 
Montville, NJ).  Body weights and food intake measurements were recorded daily and food was 
provided ad libitum.  Tumor fragments were implanted on day zero.  The mice were then 
separated into groups matched for body weights 4-7 days post implantation after imaging on the 
Xenogen Imaging System to confirm the presence of a tumor.  For the duration of the study, 
mice on calorie restriction received 40% of their normal food intake at approximately 10 AM 
(60% CR).  The AL control mice continued to receive food ad libitum.  All mice were weighed 
daily prior to food administration.  For those mice that received drug injections, a fresh stock was 
prepared and diluted to an appropriate concentration in PBS.  Drug was administered intra-
peritoneally (i.p.).  Drug was stored at 4°C for the duration of the study.  Mice were dosed at 
approximately 10 AM daily unless indicated otherwise.  For DON studies, mice received daily 
injections of either 1.0 mg/kg or 0.5 mg/kg.  Mice in the DON survival study received DON at 
either 1.0 mg/kg/day or 0.5 mg/kg/day depending on individual mouse response.  Some doses 
were skipped if the mice appeared lethargic or if body weight loss exceeded 1.5 g from the 
previous day.  For chloroquine (Sigma) studies, mice received daily injections of 45 mg/kg.  
Studies were terminated at the time of morbidity for the control group. 
 
Plasma and Serum Glucose Measurements   
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Mice were anesthetized
 
with isoflurane and euthanized by exsanguination, involving
 
collection of 
blood from the heart as previously described (Marsh et al. 2008a) or from the carotid artery via 
decapitation.  The blood was centrifuged at 4,000 x g for 20 min,
 
the plasma or serum 
supernatant was collected were stored at –80°C
 
before analysis. Blood glucose was measured
 
in a 
spectrophotometer using the appropriate enzymatic assay (Stanbio Laboratories). 
 
Histology 
Brain tumor samples were fixed in 10% neutral buffered formalin (Sigma) and embedded in 
paraffin.  The brain-tumor samples were sectioned at 5 μm, were stained with haematoxylin and 
eosin (H & E) at the Harvard University Rodent Histopathology Core Facility (Boston, MA), and 
were examined by light microscopy using either a Zeiss Axioplan 2 or Nikon SMZ1500 light 
microscope as we previously described (Mukherjee et al. 2002).  Images were acquired using 
SPOT Imaging Solutions (Diagnostic Instruments, Inc) cameras and software.  All histological 
sections were evaluated by a veterinary neuropathologist, (Roderick Bronson) at the Harvard 
University Rodent Histopathology Core Facility. 
 
PCR  
All cell lines were grown under identical conditions as described above.  VM brain and 
VM-M3 tumor samples were frozen at -80°C until time of analysis.  Single strand cDNA 
was synthesized from total RNA and used for PCR amplification as we previously 
described (Abate et al. 2006). Primer sequences used for PCR were for -actin, forward 
5-TGTGATGGTGGGAATGGGTCAG-3 and reverse 5 
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TTTGATGTCACGCACGATTTCC-3; for IGFBP-2, forward 5-
GGGTACCTGTGAAAAGAGACG-3 and reverse 5-
TGCAGGGAGTAGAGATGTTCC-3; for CXCR4, forward 5-
CTACAGCAGCGTTCTCATCC-3 and reverse 5-GGATGACTGTCGTCTTGAGG -3. 
Primers were optimized for annealing temperatures and cycle numbers as previously 
described (Abate et al. 2006).  RT-PCR products were separated on a 1-1.6% agarose gel 
containing ethidium bromide and visualized by UV light. RT-PCR was performed on the 
total RNA of each sample in the absence of reverse transcriptase to control for possible 
DNA contamination.  
 
Immunohistochemistry and Confocal Microscopy 
Cells in culture were maintained as described above. Cells were seeded in glass-
chambered slides in complete DMEM (Sigma) media.  After 24 hours cells were 
stimulated with 100 ng/ml of CXCL-12 (SDF-1) in serum free media for 30 minutes.  
Cells were washed and fixed with 4% formaldehyde for 20 minutes at 37
o
C.  After 
blocking with 10% goat serum in 0.1% BSA, cells were incubated with CXCR4 primary 
antibody (1:100) for 1 hour followed by secondary antibody (1:100) incubation for 1 hour 
at room temperature.  Cells were washed and stained with Hoechst for 10 minutes and 
mounted. Corresponding wells without primary antibody served as negative controls. 
 
For the immunohistochemical studies, the tissue sections from untreated tumor bearing 
mice were deparaffinized, rehydrated and washed.  The tissue sections were then heat 
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treated (95°C) in antigen unmasking solution (Vector Laboratories, Burlingame, CA) for 
30 min. Tissue sections were blocked in goat serum (1:10 in PBS) for one hour at room 
temperature, treated with CXCR4 primary antibody (rabbit polyclonal, 1:200 SantaCruz) 
in blocking buffer for one hour at room temperature, followed by alexafluor 585 
conjugated anti-rabbit secondary (Invitrogen) at 1:200 dilution for 45 minutes.  Sections 
were incubated with Hoechst (10g/ml) for 10 minutes and mounted. Corresponding 
tissue sections without primary antibody served as negative controls.  For confocal 
microscopy, digital images were obtained on a Leica DMI6000 inverted scope equipped 
with the Leica TCSSP5 confocal system, using HCX PL APO 40X/1.25 NA oil and HCX 
PL APO 63X/1.4 NA oil objective lenses.  Leica confocal software was used to acquire 
images.    
 
For Ki-67 staining, tissue slides were processed similarly as for CXCR4 and then treated 
with Ki-67 primary antibody (rat monoclonal, Dako, 1;100) overnight at 4°C followed by 
a biotinylated anti-rat secondary antibody at 1:100 dilution (Vector laboratories, Inc). The 
sections were then treated with avidin biotin complex followed by 3,3'-diaminobenzidine 
as substrate for staining according to the manufacturer's protocol (Vectastain Elite ABC 
kit, Vector laboratories, Inc.). The sections were counter stained with haematoxylin and 
mounted.  Corresponding tissue sections without primary antibody served as negative 
controls.  Bright field images were captured by a Zeiss Axioplan 2 light microscope. 
The percent of Ki-67 positive cells were determined using a photoshop-based image 
analysis as described previously (Lehr et al. 1999). 
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RESULTS 
 
The goal of this research was to develop a model for the study of malignant brain tumor 
growth and invasion.  Additionally, I sought to evaluate our VM-M3 cells for metabolic 
alterations that could lead to the development of a metabolic therapy. 
 
Comparison of invasive versus non-invasive brain tumors 
Figure 1 shows the gross histological phenotype of the non-invasive C57BL/6 CT-2A 
astrocytoma model and the VM-M3 brain tumor model.  The CT-2A tumor showed a 
sharp border with minimal local invasion and no distant invasion consistent with its 
previously reported behavior (Martinez-Murillo and Martinez 2007).  In contrast, the 
VM-M3 tumor showed a diffuse border with several secondary focal lesions within the 
brain parenchyma as well as in the contralateral hemisphere. 
 
Quantitative assessment of tumor growth 
We used the luciferase labeled VM-M3 tumor and monitored tumor growth non-
invasively over time (Figure 2).  The bioluminescent signal could be evaluated both 
qualitatively (Figure 2A), and quantitatively (Figure 2B) during tumor progression. 
Bioluminescence, above the lower limit of the imaging system (~ 1x10
3
 photons/sec), 
could be detected as early as day 6. 
  
Detection and quantitation of VM-M3 invading tumor cells 
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In order to quantitate the level of tumor invasion, the brains were removed at the end of 
the study and imaged ex vivo as described in Materials and Methods.  The brains were 
sectioned down the midline and each half was imaged separately.  As shown in Figure 
3A, bioluminescence was detected in both the ipsilateral and the contralateral 
hemispheres.  The level of invasion into the contralateral hemisphere was also 
quantitated.  In addition, histology was used to confirm the presence of invading tumor 
cells in both the ipsilateral and contralateral hemispheres (Figure 3B). 
 
Quantitation of distal tumor spread 
In order to further evaluate the invasion of the VM-M3 tumor cells, the removed brains 
were dissected into the cortex, hippocampus (Figure 4), brain stem, and cerebellum 
(Figure 6).  Using the Xenogen Imaging System, bioluminescence was detected and 
quantitated in all of the brain regions.  Histology was used to confirm the presence of 
invading tumor cells in the corresponding regions (Figure 5 and 7). 
 
Migratory routes of invading tumor cells 
We next identified the routes of VM-M3 tumor cell invasion (Figure 8).  We identified 
surface or sub-pial spread as the major route of invasion (Figure 8A).  However, we also 
identified tumor cells invading along and within white matter tracts, such as the corpus 
callosum and along myelinated axons crossing through the striatum (Figure 8B, C), 
through the ventricular space (Figure 8D), along blood vessels (Figure 8D) and along 
neurons (Figure 8F).   
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Expression of CXCR4 and IGFBP-2 in brain, tumor tissue, and cultured tumor cells 
As shown in Figure 9, the VM-M3 tumor cells both in vivo and in vitro expressed high 
levels of CXCR4, a chemokine receptor highly expressed in human GBM.  In addition, 
the less invasive VM-NM1 tumor from the same VM mouse host had very low CXCR4 
gene expression.  Also, we showed that insulin-like growth factor binding protein 2 
(IGFBP-2) was not highly expressed in the invasive VM-M3 cells whereas the less 
invasive VM-NM1 tumor cells had high expression of IGFBP-2.   We also found that 
CXCR4 was localized to the surface of the VM-M3 tumor cells that were grown either in 
vivo or in vitro (Figure 10).  Additionally, CXCR4 expression was found in the cells that 
had invaded throughout the brain via the sub-pial space, white matter tracts, and blood 
vessels (Figure 11). 
 
Ki-67 expression in VM-M3 tumors 
As shown in Figure 12, the VM-M3 tumors stain positive for the proliferation marker Ki-
67, indicating a high proliferation rate of these cells in vivo.  Ki-67 is a protein highly 
expressed during all phases of cell proliferation, though its specific function is largely 
unknown (Scholzen and Gerdes 2000).  High Ki-67 expression was seen in tumor cells in 
the tumor core as well as in invasive tumor cells found within the brain parenchyma 
(Figure 12).   Invasive cells staining positive for Ki-67 include those cells migrating 
through the pial membrane (Figure 12B), along blood vessels (Figure 12B, arrow), 
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through white matter tracts such as the corpus callosum (CC) (Figure 12C, arrow) and 
into the brain parenchyma (Figure 12D, arrow). 
 
Effect of calorie restriction on body weights, plasma glucose and ketones 
I next evaluated the effect of calorie restriction on body weights and circulating levels of 
glucose and ketones.  Calorically restricted mice received a 60% restriction in food intake 
as described in Materials and Methods (Figure 13). Calorie restriction significantly 
reduced the body weights of the mice over the course of the study (Figure 14A).  In 
addition, circulating glucose levels were significantly lower (Figure 14B), while 
circulating ketone levels were significantly increased (Figure 14C), in the CR group 
compared to the control ad libitum (AL) fed group. 
 
Effect of calorie restriction on tumor growth and invasion 
As seen in Figure 15, calorie restriction reduced the growth and invasion of the VM-M3 
primary tumor in mice under CR.  Compared to the diffuse, ill-defined border of the 
tumor of the AL control group, the tumor of the CR group was denser with a more 
defined border.  I evaluated the level of invasion into the contralateral hemisphere using 
bioluminescent imaging as described in the Materials and Methods.  I showed that the 
total amount of bioluminescence in the contralateral hemisphere of the CR group 
compared to the amount of bioluminescence in the contralateral hemisphere of the AL 
group was significantly reduced (Figure 16).  Histology was used to confirm the extent of 
tumor cell invasion into the contralateral hemisphere between the AL and CR groups.  As 
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shown in Figure 17, invading tumor cells were identified in all regions of the 
contralateral hemisphere of the AL group. In contrast, we only identified sub-pial spread 
to the cortex in the contralateral hemisphere of the CR group.  The number of migrating 
cells was also noticeably less in the CR mice than in the AL mice (Figure 17). In 
addition, as shown in Figure 18, the percentage of Ki-67 (+) tumor cells was significantly 
reduced in the CR group compared to the AL control group. 
 
The VM-M3 tumor as a model for systemic metastatic cancer 
As shown in Figure 19, the VM-M3 tumor is metastatic to all organs when implanted 
subcutaneously.  Tumor spread can be evaluated over time non-invasively both 
qualitatively (Figure 19A), and quantitatively (Figure 19B).  In addition, ex vivo imaging 
of the organs allows for a more specific assessment of tumor spread (Figure 19C).   
 
Effect of calorie restriction on body weights, plasma glucose and ketones 
I next evaluated the effect of calorie restriction on body weights and circulating plasma 
glucose and ketones in mice implanted subcutaneously with the VM-M3 tumor.  
Calorically restricted mice received about 40% of their normal food intake (60% CR) as 
described in Materials and Methods (Figure 20).   Calorie restriction significantly 
reduced the body weights of the calorically restricted (CR) group over the course of the 
study (Figure 21A).  In addition, CR significantly reduced circulating plasma glucose 
(Figure 21B) and significantly increased circulating plasma ketones (Figure 21C) in the 
CR group compared to the ad libitum (AL) fed group.   
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Effect of calorie restriction on tumor growth and metastasis 
As shown in Figure 22, primary tumor growth was significantly lower in the CR group 
than in the AL group.  However, metastatic spread was not statistically different between 
the control and CR group for any organ (Figure 23).  The incidence of metastatic spread 
to each organ was also not significantly different (Table 1). 
 
Differential response to energy stress between CT-2A and VM-M3 cell lines in vitro 
In order to assess the metabolic requirements of the VM-M3 cell line, a bioluminescent-
based cell viability assay was developed as described in the Materials and Methods to test 
the ability of the cells to survive under extreme energy stress in serum free media in the 
absence of either glucose or glutamine.  As shown in Figure 24, the CT-2A astrocytoma 
cell line, which has previously been shown to respond to calorie restriction, is primarily 
glycolytic and uses glucose (gluc) as its preferred fuel.  However, the VM-M3 cell line, 
which is less responsive to calorie restriction, is more dependent on glutamine (gln) than 
glucose (gluc) for energy and survival.  Because bioluminescence is directly correlated to 
ATP concentration (Supplemental Figure 5A), I show that glutamine is better able to 
support ATP production than is glucose in the VM-M3 cells. 
 
VM-M3 lactate production under energy stress 
Though lactate traditionally serves as an indicator of glycolytic flux, glutaminolysis can 
also result in the production of lactate.  As shown in Figure 25, very little lactate was 
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generated from a 24 hour incubation in glutamine.  In contrast, a significantly larger 
amount of lactate was generated from the cells incubated in glucose.  However, as shown 
previously in Figure 24, cell viability was significantly lower in glucose than in 
glutamine, indicating that VM-M3 cell survival in glutamine is independent of glycolysis 
or lactate production. 
 
VM-M3 cell survival in both glucose and glutamine 
In order to determine if glucose and glutamine act synergistically to promote cell survival 
in the VM-M3 cell line, the two metabolites were tested together in culture (Figure 26).  
Cell viability and hence ATP production was significantly enhanced relative to viability 
in either metabolite alone.  In addition, the production of lactic acid was enhanced when 
the two metabolites were combined (Figure 27), suggesting that glycolysis and 
glutaminolysis acted synergistically to maintain cell viability and growth. 
 
Survival of VM-M3 cells in varying glucose and glutamine concentrations 
VM-M3 cells were incubated in varying concentrations of glucose and glutamine.  As 
shown in Figure 28, when the glucose concentration was held constant while reducing the 
glutamine concentration, a corresponding reduction in cell viability was observed.  
However, when the glutamine concentration was held constant, we see that only small 
amounts of glucose were necessary to maintain a constant level of cell viability.  This 
again suggests that the VM-M3 cells rely more on glutamine than glucose for energy and 
cell survival. 
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Effect of meso-Tartrate on VM-M3 cell viability 
Meso-Tartrate, a malate analog, is an inhibitor of malic enzyme (Supplemental Figure 3) 
(Do Nascimento et al. 1975).  Current hypotheses suggest that cytosolic malic enzyme is 
responsible for generating pyruvate from glutamine-derived malate (DeBerardinis et al. 
2007).  Meso-Tartrate had little effect on glutamine metabolism (Figure 29).  
Interestingly, meso-Tartrate had a significant effect on cell viability when in the presence 
of both glucose and glutamine, suggesting that meso-Tartrate is potentially inhibiting 
glycolysis.  In support of this, lactic acid was significantly reduced when the VM-M3 
cells were incubated in both glucose and glutamine in the presence of meso-Tartrate 
(Figure 30).   Additionally, there was no reduction in lactate production when the VM-
M3 cells were incubated in glutamine and meso-Tartrate (Figure 30). 
 
Effect of the TCA cycle inhibitor 3-Nitropropionic acid (3-NP) on VM-M3 cell viability 
I next sought to determine the effect of the TCA cycle inhibitor 3-NP on VM-M3 cell 
viability and ATP production while under energy stress (Supplemental Figure 3).  As 
shown in Figure 31, 3-NP caused a significant reduction in cell viability when the cells 
were in media containing glutamine.  Incubation of VM-M3 cells in glucose alone with 
3-NP had only a slight effect on cell viability.  Therefore this suggests that 3-NP is 
specific to glutamine metabolism and that the VM-M3 cells generate a significant amount 
of ATP from glutamine. 
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Effect of fatty acid metabolism on VM-M3 cell viability 
Because a large amount of lactic acid is generated from glucose derived pyruvate, an 
additional source of acetyl-CoA would be necessary for continued TCA cycling and 
glutamine metabolism.  As shown in Figure 32, the addition of heptanoic acid, a short 
chain fatty acid, significantly enhanced VM-M3 survival when in the presence of 
glutamine.  Thus acetyl-CoA can continually feed in to the TCA allowing for glutamine 
metabolism to maintain cell viability and ATP production. 
 
Effect of ketones on VM-M3 cell viability in vitro 
As shown in Figure 33, the addition of 10mM -hydroxybutyrate was not toxic to the 
VM-M3 cells.  The presence of -hydroxybutyrate was however slightly but significantly 
inhibitory in the presence of glutamine alone. 
 
Oligomycin sensitivity of VM-M3 and CT-2A tumor cell lines 
As shown in Figure 34, both the VM-M3 and CT-2A cell lines were able to maintain a 
sufficient level of ATP over 2 hours in media containing 5ug/ul oligomycin, the F1-
ATPase inhibitor (Supplemental Figure 3).  A short incubation time was used to eliminate 
non-specific toxicity as described previously (Matheson et al. 2007).  In addition, after 1 
hour in oligomycin, the CT-2A cells had a lower amount of ATP compared to the 
controls, but produced significantly more lactic acid, consistent with the upregulation of 
glycolysis in response to an inhibition of respiration (Figure 35).  This suggests that in 
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both CT-2A and VM-M3 cell lines, metabolism of glucose and glutamine occurs 
respectively in the absence of a functional respiratory capacity. 
 
Effect of diadenosine pentaphosphate (Ap5A) on VM-M3 cell viability 
As shown in Figure 36, incubation of the VM-M3 cells with the adenylate kinase 
inhibitor Ap5A resulted in a significant reduction in cell viability when glutamine was 
the only metabolite present.  There was no significant effect of Ap5A on the VM-M3 
cells in either gluc + gln or gluc alone.  This suggests that ATP generated from glutamine 
in the mitochondria is heavily dependent on efficient phosphate transfer reactions 
particularly in the absence of cytosolic ATP. 
 
In vitro effect of 6-Diazo-5-oxo-L-norleucine (DON) on the VM-M3 cell line  
As shown in Figure 37, DON was effective in inhibiting cell growth over 48 hours at 
both low (50 μM) and high (250 μM) concentrations.  Over the first 24 hours DON did 
not cause cell death but rather inhibited cell growth compared to the non-drug control.  A 
slight reduction in cell viability was observed over 48 hours. 
 
Effect of DON and DON + CR on body weights, blood glucose and ketones 
I next evaluated the effect of DON alone and in conjunction with calorie restriction on 
body weights and blood glucose levels in mice implanted subcutaneously with the VM-
M3 tumor.   DON was administered beginning on day 5 at an initial dose of 1 mg/kg/day 
(Figure 38).  Over the course of the study, dosing was adjusted based on individual 
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mouse response as described in Materials and Methods.  As shown in Figure 39A, the 
body weights of DON treated mice were similar during drug treatment compared to the 
control mice.  However, the body weights of DON treated mice declined over the last 3 
days of the study.   The DON + CR mice showed a steady decrease in body weight which 
was maintained over the last 2 days of the study. As shown in Figure 39B, blood glucose 
levels were similar between the DON group and control group, though blood glucose 
levels were significantly lower in the DON + CR group compared to the control or DON 
group.  In addition, circulating blood ketones were elevated in the DON + CR group 
compared to the DON group (Figure 39C). 
 
Effect of DON and DON + CR on tumor growth and metastasis 
As shown in Figure 40, the removed tumors from both DON treated groups were 
significantly smaller compared to the control mice. The control mice had an average 
tumor weight of approximately 2.0 g.  However, both DON treated groups had an 
average tumor weight of 0.1 g, nearly 20-fold less than the control mice.  As seen in 
Figure 41, the control mice had tumor metastasis to the liver, lung, kidney, and spleen, 
consistent with the behavior of this tumor (Huysentruyt et al. 2008).  However, both 
DON treated groups had no detectable metastasis to the liver, lung, or kidney.  In 
addition, I examined liver histology because it is an organ most heavily infiltrated with 
tumor cells from the control group and is found in 100% of the control mice.  As shown 
in Figure 42, histological analysis confirmed the lack of tumor cells in the liver of the 
DON and DON + CR treated mice in comparison to the control AL non-treated mouse 
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group.  Interestingly, both DON treated groups did have metastasis to the spleen.  Spleen 
bioluminescence was not significantly different between the control and either DON 
treated groups.  However, using a chi square analysis, the incidence of metastasis to 
spleen was significantly lower in the DON + CR group than in the untreated controls 
(Table 2). 
 
Effect of DON and DON + CR on mouse survival 
As seen in Figure 43, all control mice reached morbidity 15-19 days post implantation.  
However, mice in the DON and DON + CR groups survived significantly longer.  The 
DON treated group reached morbidity due to extreme drug toxicity as indicated by loss of 
body weight, hind leg paralysis, and urinary blockages.  The primary tumors in the DON 
treated mice remained small and systemic metastasis detected with bioluminescent 
imaging was not apparent (data not shown).  The DON + CR group however survived 
longer without any signs of toxicity.   However, drug toxicity did eventually become 
apparent in the DON + CR group as well.  
 
The aim of this last section was to determine if the VM-M3 cells were capable of 
generating ATP from the digestion of phagocytosed material and if this occurred 
primarily while under energy stress.  Finally, the goal was to determine if this phagocytic 
property could be exploited for therapeutic options. 
 
Effect of cholorquine (CQ) on CT-2A and VM-M3 cell viability in vitro 
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As shown in Figure 44, chloroquine, the lysosomal enzyme inhibitor, had no inhibitory 
effect on CT-2A cells grown in culture and may have been stimulatory at low 
concentrations.  However, CQ did display a dose dependent toxicity toward the VM-M3 
cells in culture over 24 hours. 
 
Effect of chloroquine on VM-M3 cell viability in a Matrigel Matrix 
In order to test the phagocytic capabilities of the VM-M3 cells, I developed an assay 
within a 3-dimensional Matrigel matrix.  As shown in Figure 45A, over 24 hours 20μM 
chloroquine caused a slight reduction in VM-M3 cell viability in complete media and no 
significant reduction in VM-M3 cell viability in Matrigel plus complete media.  
Additionally, as shown in Figure 45B, VM-M3 cell viability was significantly reduced 
when grown in a glucose media in the absence of glutamine or FBS.  The presence of 
Matrigel however significantly increased VM-M3 cell viability (Figure 46).  In 
addition, chloroquine caused significant cell death in the VM-M3 cells when under 
energy stress either in the presence or absence of Matrigel.  This indicated that these 
cells were potentially capable of generating energy from phagocytosed components only 
while under energy stress.  In support of this, as shown in Figure 47, the cells incubated 
in glucose + Matrigel generated significantly more lactic acid in the media than those 
cells in glucose alone, indicating that components of the carbohydrate rich Matrigel 
matrix were being used via glycolysis to generate energy. 
 
Effect of chloroquine on CT-2A cell viability in a Matrigel Matrix 
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Similar to the VM-M3 cells, over 24 hours 20μM chloroquine did not cause a significant 
reduction in CT-2A cell viability in complete media or in Matrigel plus complete 
media (Figure 48A).  Additionally, as shown in Figure 48B, CT-2A cell viability was 
significantly reduced when the cells were grown in a media containing only glutamine. 
Unlike VM-M3 cells, the presence of Matrigel did not rescue the CT-2A cells when 
placed under energy stress in a media containing only glutamine (Figure 49).  In addition, 
chloroquine had no effect on CT-2A cell survival while under energy stress.  This 
indicated that the CT-2A cells differed from the VM-M3 cells in that they were unable to 
use phagocytosis as a mechanism to acquire nutrients during times of energy stress. 
 
Latex bead phagocytosis 
As shown in Figure 50 using confocal microscopy, the VM-M3 cells phagocytosed un-
opsinized latex beads. Additionally, when placed under energy stress, the VM-M3 cells 
internalized collagen coated latex beads resulting in a significant increase in survival 
relative to a non-coated latex bead control (Figure 51).  However, as shown in Figure 52, 
the presence of collagen coated latex beads did not result in an increase in either lactate 
or ammonia accumulation in the media compared to the uncoated controls. 
 
Effect of chloroquine on tumor growth and metastasis 
I next evaluated the effect of chloroquine in conjunction with calorie restriction on VM-
M3 tumor growth and metastasis (Figure 53).  As shown in Figure 54, CQ had a slight 
but not significant inhibitory effect on the size of the primary tumor in mice treated with 
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CQ only compared to the controls.  However, as seen in Figure 55, CQ treatment had no 
effect on metastasis.  As seen in Figure 56, the combination of CR and CQ did not act 
synergistically and no further reduction in primary tumor wet weight was observed 
compared to the CR group.  Additionally, as seen in Figure 57, the combination of CR 
and CQ did not have any inhibitory effect on metastatic spread compared to either the 
control or the CR group. 
 
Effect of Chloroquine on brain tumor growth and invasion 
Chloroquine in conjunction with calorie restriction was also evaluated on VM-M3 brain 
tumor growth and invasion (Figure 58).  As shown in Figure 59, CQ had no effect on 
brain tumor growth or invasion in mice treated with CQ alone compared to the controls.   
Additionally, as seen in Figure 60, the combination of CR and CQ did not act 
synergistically and no further reduction in tumor invasion was observed compared to the 
CR group. 
 
Astrocyte transition to a low glucose, high ketone media in vitro 
As shown in Supplemental Figure 1, in vitro, astrocytes successfully transitioned to a 
high ketone, low glucose media.  VM-M3 cells were unable to transition and no cell 
survival was apparent compared to the astrocytes. 
 
Effect of phenylbutyrate (PBA) on VM-M3 survival in vitro 
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As shown in Supplemental Figure 2, PBA showed a does dependent effect on VM-M3 
cell survival compared to the non-drug treated controls. 
 
Correlation between ATP concentration, cell number and bioluminescence 
As shown in Supplemental Figure 5, quantitation of bioluminescence can be directly 
correlated to both ATP concentration (Supplemental Figure 5A) and cell number 
(Supplemental Figure 5B). 
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Figure 1.  Comparative analysis of the growth behavior of mouse brain tumors, 
VM-M3 and the CT-2A malignant astrocytoma.  Small tissue fragments from the CT-
2A and VM-M3 tumors were implanted into the right cerebral hemisphere (i.c.) of their 
syngeneic host C57BL/6J and VM strains, respectively. Brains were removed 
approximately 11-15 days post implantation and were stained with haematoxylin and 
eosin (H & E) as described in Materials and Methods.  The CT-2A tumor shows a distinct 
tumor border with little local invasion and no distant invasion.  The VM-M3 tumor is 
highly invasive both locally and distally with numerous secondary tumor lesions 
(arrows).  Images are shown at 7.5x. 
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Figure 2. Growth of the VM-M3/Fluc tumor with bioluminescence imaging.  (A) 
VM-M3/Fluc tumor fragments were implanted as described in Figure 1.  Cranial images 
were taken over 15 days (representative mouse shown).  (B) Bioluminescence from the 
whole mouse was quantified and plotted on a log scale.  All values are expressed as the 
mean of 6 independent samples ± SEM. 
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Figure 3.  Detection of VM-M3/Fluc tumor cell invasion into the contralateral 
hemisphere with bioluminescent imaging and histology.  (A) VM-M3/Fluc tumor 
fragments were implanted as described in Figure 1.  Removed brains were dissected into 
ipsilateral and contralateral hemispheres.  Each hemisphere was imaged for 
bioluminescence ex vivo as described in Materials and Methods.  Bioluminescence from 
each brain half was quantified and plotted on a log scale.  Bioluminescence in the 
contralateral hemisphere is indicative of distal tumor spread.  The values are expressed as 
means ± SEM of six independent tumor-bearing mice.  (B) Histological analysis (H&E) 
was used to validate the presence of tumor cells in the contralateral hemisphere as 
described in Materials and Methods. Tumor cells are shown in the contralateral 
hemisphere invading the neural parenchyma from the sub pial membrane (arrows).  
Images are shown at 200X. 
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Figure 4.  Bioluminescent analysis of distal tumor spread to the cortex and 
hippocampus. VM-M3/Fluc tumor fragments or cells were implanted as described in 
Figure 1.  Removed brains were sectioned through the midline and were further dissected 
into the cortex and hippocampus of the ipsilateral (I) and contralateral (C) hemispheres.  
Bioluminescence was quantified and plotted on a log scale. All values are expressed as 
the mean ± SEM of 10 independent samples. 
n = 10
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Figure 5.  Histological evaluation of distal tumor spread to the cortex and 
hippocampus. VM-M3/Fluc tumor fragments or cells were implanted as described in 
Figure 1.  Histological analysis (H&E) was used to validate the presence of tumor cells as 
described in Materials and Methods.  Top panel images are shown from left to right at 
100X, 50X, 50X, and 100X. The black boxes from the top panel images are shown in 
higher power in the bottom panel. Bottom panel images are shown from left to right at 
400X, 200X, 200X, and 400X.  Arrows indicate invasive tumor cells. 
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Figure 6.  Bioluminescent analysis of distal tumor spread to the brain stem and 
cerebellum.   VM-M3/Fluc tumor fragments or cells were implanted as described in 
Figure 1.  Removed brains were sectioned down the midline and were further dissected 
into cerebellum and brain stem.  Bioluminescence was quantified and plotted on a log 
scale. All values are expressed as the mean ± SEM of 10 independent samples. 
n = 10
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Figure 7.  Histological evaluation of distal tumor spread to the brain stem and 
cerebellum. VM-M3/Fluc tumor fragments or cells were implanted as described in 
Figure 1. Histological analysis (H&E) was used to validate the presence of tumor cells as 
described in Materials and Methods.  Top panel images are shown at 50X.  The scale bar 
represents 250 μm.  The black boxes from the top panel images are shown in higher 
power in the bottom panel.  Bottom panel images are shown at 200X.  Arrows identify 
subpial tumor cell spread in the cerebellum and tumor cell invasion in the brain stem.  
The dashed line demarcates the ipsilateral from the contralateral side of brain stem. 
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Figure 8.  Migratory routes of the VM-M3/Fluc brain tumor cells.  VM-M3/Fluc 
tumor fragments or cells were implanted as described in Figure 1. Histological analysis 
(H&E) was used to validate the presence of tumor cells as described in Materials and 
Methods.  The VM-M3/Fluc tumor cells are shown invading along the pial surface 
(arrow, A), within the corpus callosum (CC, arrow, B), along myelinated axons crossing 
through the striatum (arrow, C), through the ventricular system (arrows, D), around the 
blood vessels (arrow, E), and around neurons (arrow, F). Images are shown at 100X (A), 
50X (B), 400X (C), 200X (D), and 400X (E and F).  Arrows identify regions containing 
tumor cells. 
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Figure 9.  Expression of CXCR4 and IGFBP-2 in brain, tumor tissue, and in 
cultured tumor cells.  CXCR4 and IGFBP-2 gene expression was determined by semi-
quantitative RT-PCR as described in Materials and Methods.  
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Figure 10.  CXCR4 protein localization in VM-M3 tumor and cells in vitro.  CXCR4 
protein localization was determined in vitro and in vivo as described in Materials and 
Methods.   Images are shown at 400X, and 630X (insert).  Scale bars in the insert 
represent 10μm. 
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Figure 11.  Expression of CXCR4 in invasive VM-M3 tumor cells in vivo.  CXCR4 
protein localization was determined as described in Materials and Methods.  Images are 
shown at 630X.  The scale bar is representative of all images shown.  Arrows indicate 
regions of positive CXCR4 expression.  The arrow in the top panel illustrates tumor cells 
invading into the brain parenchyma from the tumor mass (T) under the pial membrane.  
(BV = blood vessel, P = normal brain parenchyma, T = tumor, WM = white matter) 
S
u
b
-P
ia
l
In
tr
a
-F
a
s
c
ic
u
la
r
P
e
ri
-V
a
s
c
u
la
r
T
W
M
2
5
μm
1
0
0
μm
1
0
0
μm
C
X
C
R
4
H
o
e
c
h
s
t
M
e
rg
e
B
V
W
M
5
0
 μ
mT
P
P
P
65
 66
Figure 12.  Ki-67 expression in VM-M3 tumor.   (A) Ki-67 expression in normal brain 
and in the tumor core was determined as described in Materials and Methods. The black 
boxes from the top panel images are shown under higher digital zoom in the bottom 
panel.  Ki-67 expression in the invasive tumor cells found migrating through the pial 
membrane (B), around blood vessels (B, arrow), within white matter (C), and invading 
into the brain paryenchyma (D).  Images are shown at 400X.  Scale bars are 
representative of all images of that panel.  Arrows indicate tumor cells staining positive 
for Ki-67 (brown).  (CC = corpus callosum) 
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Figure 13. Experimental Design.  VM mice were implanted with the VM-M3/Fluc 
tumor i.c. as described in Materials and Methods and were given a 60% CR starting on 
day 4-6.  Brains were removed 12-15 days post implantation and imaged ex vivo.  
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Figure 14.  Effect of calorie restriction on VM-M3/Fluc tumor bearing mice.  VM 
mice were implanted with the VM-M3/Fluc tumor i.c. as described in Materials and 
Methods.  (A) The body weights of the VM mice were monitored daily. Values represent 
the mean ± SEM of 9-10 mice per group.  VM mice were sacrificed and plasma was 
collected for the analysis of glucose (B) and ketone (C) levels using an enzymatic assay.  
Values represent the mean ± SEM. The asterisk indicates that the CR values differ 
significantly from the AL control group at p < 0.05.  
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Figure 15.  Influence of calorie restriction on VM-M3/Fluc tumor growth 
VM-M3/Fluc tumor fragments were implanted i.c. as described in Materials and 
Methods.  Post imaging, brains were fixed and stained with haematoxylin and eosin (H & 
E) as described in Materials and Methods.   Images are shown at 50X (T=tumor, 
H=Hippocampus). At least 3 samples were examined per experimental group. 
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Figure 16.  Influence of calorie restriction on bioluminescence in the contralateral 
hemisphere.  VM-M3/Fluc tumor fragments were implanted as described previously.  
Each hemisphere was imaged for bioluminescence ex vivo as described in Materials and 
Methods.  The bioluminescence given off from each hemisphere was added for a total 
bioluminescence value (photons/sec).  Data for the contralateral hemisphere is expressed 
as the percent of the total photons/sec.  Values represent the mean ± SEM of 9-10 mice 
per group.  Representative bioluminescent images are shown.  The asterisk indicates that 
the CR values differ significantly from the AL control group at p < 0.05.  
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Figure 17.  Influence of calorie restriction on VM-M3/Fluc tumor cell invasion to the 
contralateral hemisphere.  VM-M3/Fluc tumor fragments were implanted as described 
in Materials and Methods. Histological analysis (H&E) was used to validate the presence 
of tumor cells as described in Materials and Methods.  Top panel images (AL) are shown 
from left to right at 200X, 100X, 100X, and 200X.  Bottom panel (CR) images are shown 
from left to right at 200X, 100X, 100X, and 200X.  At least 3 samples were examined per 
experimental group. 
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Figure 18.  Influence of calorie restriction on Ki-67 staining in the primary tumor 
Tissue sections were stained and quantitated for Ki-67 (+) tumor cells as described in the 
Materials and Methods.  Three independent areas were quantitated per tumor sample and 
averaged for a single value.  Values represent the mean ± SEM of 3 independent samples 
per group.  The asterisk indicates that the values for the CR group differ from those of the 
AL control group at a p < 0.05.  Representative immunohistological sections are shown.  
Images are shown at 400X.  (Ki-67 (+) = brown, arrows) 
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Figure 19.  Growth and metastatic spread of the VM-M3/fluc tumor with 
bioluminescence imaging.  Tumors were implanted s.c as described in the Materials and 
Methods.  (A) Dorsal (upper panels) images were taken over 23 days.  Ventral (lower 
panel) images were taken once metastasis was detectable (representative mice shown).  
(B) Bioluminescence from the whole mouse (dorsal and ventral images added together) 
was quantified and plotted on a log scale. (C) At the end of the study organs were 
removed and imaged ex vivo in 300 μg/ml D-luciferin in PBS from 1-15 min and 
metastasis was quantified and plotted on a log scale.  All values are expressed as the 
means of 6 independent samples ± 95% C.I. 
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Figure 20. Experimental design.  VM mice were implanted with the VM-M3/Fluc 
tumor s.c. as described in Materials and Methods and were given a 60% CR starting on 
day 5-7.  Organs were removed 15-19 days post implantation and imaged ex vivo. 
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Figure 21.   Effect of calorie restriction on VM-M3/Fluc tumor bearing mice.  VM 
mice were implanted with the VM-M3/Fluc tumor s.c. as described in Materials and 
Methods.  (A) Body weights were monitored daily.  Mice were sacrificed 15-19 days post 
implantation and blood was collected for the analysis of glucose (B) and ketone (C) 
levels using an enzymatic assay.  All values represent the mean ± SEM.  CR values differ 
significantly from the AL control group at * p < 0.05, **p < 0.01. 
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Figure 22.  Effect of calorie restriction on VM-M3/Fluc primary tumor size.  VM 
mice were implanted with the VM-M3/Fluc tumor s.c. as described in Materials and 
Methods.  Mice were sacrificed 15-19 days post implantation and the tumors removed 
and weighed.  CR significantly reduced the size of the tumor by approximately half.  All 
values represent the mean ± SEM of 10-24 mice per group. The asterisks indicate that the 
CR values differ significantly from the AL control group at p < 0.01. 
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Figure 23.  Effect of calorie restriction on VM-M3/Fluc tumor metastasis. VM mice 
were implanted with the VM-M3/Fluc tumor s.c. as described in Materials and Methods.  
Mice were sacrificed 15-19 days post implantation and the organs were removed and 
were imaged ex vivo. Bioluminescence values were plotted on a log scale.  All values 
represent the mean ± SEM of 8-24 mice per group.  There is no statistically significant 
difference between the AL and CR group for any organ. 
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Figure 24.  A differential response to energy stress in vitro between CT-2A and VM-
M3 tumor cell lines.   Approximately 5 x 10
4
 cells were seeded in 24 well plates. Cells 
were immediately imaged in order to obtain a 0 hr baseline bioluminescent value as 
described in Materials and Methods.  Cells were allowed to settle for 6-9 hours before the 
addition of minimal DMEM media containing either 25 mM glucose or 4 mM glutamine.  
Cell viability was assessed 24 hours later via bioluminescent imaging.  Results show that 
glucose is more important then glutamine for survival of CT-2A cells while glutamine is 
more important than glucose for survival of VM-M3 cells.  Data are expressed as the 
mean percent increase in cell number relative to the 0 hr time point ± 95% C.I. of 3-4 
independent samples per group.  The asterisks indicate that the gln values differ 
significantly from the gluc values at a p < 0.01.   
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Figure 25.  VM-M3 lactate production under energy stress.  Cells were incubated in 
minimal DMEM media containing either 25mM glucose or 4mM glutamine for 24 hours 
as described in Materials and Methods.  Media aliquots from each group were taken after 
24 hours.  Lactate accumulation was determined using an appropriate enzymatic assay.  
Results show that glutamine metabolism does not result in significant lactate production.    
Values represent the mean ± 95% C.I. of 3 independent samples per group. The asterisks 
indicate that the gln value differs significantly from the gluc value at a p < 0.01. 
 
L
a
c
ta
te
 (
M
) n = 3
**
93
 94
Figure 26.  Effect of glucose and glutamine on VM-M3 viability. VM-M3 cells were 
seeded as described in Figure 24.  After 24 hours, cell viability was assessed via 
bioluminescent imaging.  Glucose and glutamine significantly enhanced cell growth 
compared to either metabolite alone.  Data are expressed as the mean percent increase in 
cell number relative to the 0 hr time point ± 95% C.I. of 4 independent samples per 
group.  The asterisks indicate that the gluc + gln values differ significantly from the gluc 
or gln values at a p < 0.01. 
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Figure 27.  VM-M3 lactate production in the presence of both glucose and 
glutamine.  VM-M3 cells were incubated in minimal DMEM media containing both 
25mM glucose and 4mM glutamine for 24 hours as described in Figure 24.  Media 
aliquots from each group were taken after 24 hours.  Lactate accumulation was 
determined using an appropriate enzymatic assay.  Incubation in glucose and glutamine 
resulted in a significant increase in lactate production relative to either metabolite alone.  
Values represent the mean ± 95% C.I. of 3 independent samples per group.  The asterisks 
indicate that the gluc + gln values differ significantly from the gluc or gln values at a p < 
0.01. 
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Figure 28.  VM-M3 cell viability in varying glucose and glutamine concentrations.  
VM-M3 cells were seeded as described in Figure 24.  After 24 hours, cell viability was 
assessed via bioluminescent imaging.  Data are expressed as the mean percent increase in 
cell number relative to the 0 hr time point ± 95% C.I. of 4 independent samples per 
group. 
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Figure 29.   Effect of meso-Tartrate on VM-M3 cell viability under energy stress. 
VM-M3 cells were seeded as described in Figure 24 in the presence or absence of 3mM 
meso-Tartrate. After 24 hours, cell viability was assessed via bioluminescent imaging.  
Meso-Tartrate significantly reduced cell viability in gluc + gln, but not in gln alone.  Data 
are expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 4 independent samples per group.  The asterisks indicate that the gluc + gln + 
meso-Tartrate values differ significantly from the gluc + gln values at a p < 0.01. 
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Figure 30.  Effect of meso-Tartrate on VM-M3 lactate production.   VM-M3 cells 
were seeded as described in Figure 24 in the presence or absence of 3mM meso-Tartrate.  
Media aliquots were taken after 24 hours.  Lactate accumulation was determined using an 
appropriate enzymatic assay.  Meso-Tartrate significantly reduced lactate production in 
gluc + gln, but not in gln alone.  Values represent the mean ± 95% C.I. of 3-4 
independent samples per group. The asterisks indicate that the gluc + gln + meso-Tartrate 
values differ significantly from the gluc + gln values at a p < 0.01. 
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Figure 31.   Effect of 3-Nitropropionic acid (3-NP) on VM-M3 cell viability under 
energy stress. VM-M3 cells were seeded as described in Figure 24 in the presence or 
absence of 2mM 3-NP. After 24 hours, cell viability was assessed via bioluminescent 
imaging.  Data are expressed as the mean percent increase in cell number relative to the 0 
hr time point ± 95% C.I. of 4 independent samples per group.  The asterisks indicate that 
the 3-NP values differ significantly from the corresponding condition without 3-NP at a p 
< 0.01. 
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Figure 32.  Effect of fatty acid metabolism on VM-M3 cell viability in glutamine. 
VM-M3 cells were seeded as described in Figure 24 in the presence or absence of 1mM 
heptanoic acid (HA) in 4mM glutamine (gln).  After 24 hours, cell viability was assessed 
via bioluminescent imaging.  VM-M3 cell viability was enhanced in gln + HA relative to 
either metabolite alone.  Data are expressed as the mean percent increase in cell number 
relative to the 0 hr time point ± 95% C.I. of 3-4 independent samples per group.  The 
asterisks indicate that the gln + HA values differ significantly from the gln or HA values 
at a p < 0.01. 
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Figure 33.  Effect of ketones on VM-M3 cell viability in vitro.  VM-M3 cells were 
seeded as described in Figure 24 in the presence or absence of 10 mM -
hydroxybutyrate.  After 24 hours cell viability was assessed via bioluminescent imaging.  
VM-M3 cell viability was unaffected by the presence of -hydroxybutyrate in gluc + gln 
and in gluc alone.  VM-M3 cell viability was slightly reduced in the presence of -
hydroxybutyrate in a gln media. Data are expressed as the mean percent increase in cell 
number relative to the 0 hr time point ± 95% C.I. of 3 independent samples per group.  
The asterisks indicate that gln + -OHB was significantly less than gln at a p < 0.01. 
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Figure 34.  Effect of oligomycin on VM-M3 and CT-2A cell viability under energy 
stress.  VM-M3 and CT-2A cells were seeded as described in the Materials and Methods 
in the presence or absence of 5μg/μl oligomycin in 4mM glutamine (VM-M3) or 25mM 
glucose (CT-2A).   Cell viability was determined over 2 hours via bioluminescent 
imaging.  Both cell lines maintained viability in the presence of the inhibitor.  Data are 
expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 3- 4 independent samples per group.  
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 Figure 35.  Effect of oligomycin on CT-2A lactate production.   CT-2A cells were 
seeded as described in the Materials and Methods in the presence or absence 5μg/μl 
oligomycin in 25mM glucose.  Media aliquots were taken after each time point.  Lactate 
accumulation was determined using an appropriate enzymatic assay.  Lactate levels were 
increased in the presence of the F1-ATPase inhibitor.  Values represent the mean ± 95% 
C.I. of 3-4 independent samples per group.  The asterisk indicates that the gluc + oligo 
values differ significantly from the control values at a p < 0.05. 
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Figure 36.  Effect of diadenosine pentaphosphate (Ap5A) on VM-M3 cell viability 
under energy stress.  VM-M3 cells were seeded as described in Figure 24 in the 
presence or absence of 175μM Ap5A. After 24 hours, cell viability was assessed via 
bioluminescent imaging.  VM-M3 cell viability was significantly reduced in the presence 
of Ap5A in gln.  Ap5A did not significantly affect viability in gluc + gln or in gluc alone.  
Data are expressed as the mean percent increase in cell number relative to the 0 hr time 
point ± 95% C.I. of 4 independent samples per group.  The asterisks indicate that the gln 
+ Ap5A values differ significantly from the gln values at a p < 0.01. 
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Figure 37. Effect of 6-diazo-5-oxo-L-norleucine (DON) on VM-M3 cell viability in 
vitro.  VM-M3/Fluc cells were seeded in DMEM in 24 well plates as described in the 
Materials and Methods and treated with DON (50 and 250 μM).  Cells were imaged 
every 24 hours using the Xenogen IVIS system.  DON treatment significantly reduced 
cell growth over 48 hours.  Data are expressed as the mean percent increase in cell 
number relative to the 0 hr time point ± 95% C.I. of 4 independent samples per 
concentration. 
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Figure 38.  Experimental design. VM mice were implanted with the VM-M3/Fluc 
tumor tissue s.c. as described in Materials and Methods.  DON administration began on 
day 5.  Organs were removed 15-19 days post implantation and imaged ex vivo.  
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Figure 39.  Effect of DON and DON + CR on VM-M3/Fluc tumor bearing mice.  
VM mice were implanted with the VM-M3/Fluc tumor s.c. as described in the Materials 
and Methods.  (A) Body weights were monitored daily.  Mice were sacrificed 15-19 days 
post implantation and blood was collected for the analysis of glucose (B) and ketone (C) 
levels as described in the Materials and Methods.  All values represent the mean ± SEM.  
The DON + CR values differed significantly from the values of the AL control group at 
*p < 0.05, **p < 0.01.  The ‡ indicates that the DON + CR values differed significantly 
from the values of the DON group at a p < 0.01. 
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Figure 40.  Effect of DON and DON + CR on VM-M3/Fluc tumor growth.  VM mice 
were implanted s.c. with the VM-M3/Fluc tumor as described in Materials and Methods. 
The mice were sacrificed 15-19 days post implantation and the tumors were removed and 
weighed. DON treatment in both groups resulted in an approximate 20-fold reduction in 
primary tumor size.  The asterisks indicate that the DON or DON + CR values differ 
significantly from the AL control group at p < 0.01.  Representative images are shown.  
The dotted line demarcates the tumor border. 
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Figure 41.  Effect of DON and DON + CR on VM-M3/Fluc tumor metastasis. VM 
mice were implanted s.c. with the VM-M3/Fluc tumor as described in Materials and 
Methods. The organs were removed 15-19 days post implantation and imaged ex vivo.  
Bioluminescence values were plotted on a log scale.  No detectable bioluminescence was 
found in the liver, lung, and kidney of mice treated with DON or DON + CR.  All values 
represent the mean ± SEM. 
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Figure 42.  Influence of DON and DON + CR on liver histology. VM mice were 
implanted s.c. with the VM-M3/Fluc tumor as described in Materials and Methods. 
Removed livers were stained with haematoxylin and eosin (H & E) as described in 
Materials and Methods.  Arrows indicate secondary tumor lesions in the control untreated 
group only. Images are shown at 100X (top panel) and 200X (bottom panel).  The liver 
from a non-tumor bearing mouse also served as a control. 
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Figure 43.  Influence of DON and DON + CR on VM mouse survival.  VM mice were 
implated s.c. with the VM-M3/Fluc tumor as described in Materials and Methods.   All 
control mice reached morbidity 15-19 days post implantation. Both DON treated groups 
survived significantly longer than the controls. Survival was also significantly longer in 
mice treated with DON + CR than those treated with DON alone at a p < 0.01. 
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Figure 44. Effect of Chloroquine (CQ) on VM-M3 and CT-2A cell viability in vitro. 
VM-M3/Fluc and CT-2A/Fluc cells were seeded in DMEM in 24 well plates as described 
in the Materials and Methods and treated with CQ (0-20 μM).  Cells were imaged after 
24 hours using the Xenogen IVIS system.   VM-M3 cell viability was more sensitive to 
CQ treatment than were the CT-2A cells.  Data are expressed as the mean percent 
increase in cell number relative to the non-drug control ± 95% C.I. of 4 independent 
samples per concentration. 
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Figure 45.  In vitro effect of Chloroquine on VM-M3 cell viability in 
MatrigelMatrix.  (A) VM-M3 cells were seeded in 24 well plates as described in 
Materials and Methods in the presence or absence of MatrigelMatrix (MG) ± 20 μM 
CQ in complete DMEM.  Cell viability was assessed 24 hours later via bioluminescent 
imaging.  VM-M3 cell viability was unaffected by CQ when in a complete media.  Data 
are expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 3-6 independent samples per group. (B) Reduction in viability in VM-M3 
cells when seeded in 5 mM glucose compared to complete DMEM (comp).  Data are 
expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 6 independent samples per group. The asterisks indicate that viability in the 
glucose group differs significantly from the complete DMEM control group at p < 0.01. 
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Figure 46.  In vitro effect of Chloroquine and MatrigelMatrix on VM-M3 cell 
viability while under energy stress.  VM-M3 cells were seeded in 24 well plates as 
described in Materials and Methods in the presence or absence of MatrigelMatrix ± 20 
μM CQ in 5 mM glucose.  Cell viability was assessed 24 hours later via bioluminescent 
imaging.  VM-M3 cell viability was significantly enhanced by the presence of the 
MatrigelMatrix.  CQ treatment resulted in near complete VM-M3 cell death.  Data are 
expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 6 independent samples per group.  The asterisk indicates that the Matrigel 
values differ significantly from the non-matrigel control group at p < 0.05.  
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Figure 47.  Effect of MatrigelMatrix on VM-M3 lactate production under energy 
stress.  VM-M3 cells were seeded as described in Figure 45.  Media aliquots from each 
group were taken after 24 hours.  Lactate accumulation was determined using an 
appropriate enzymatic assay.  VM-M3 cells produced more lactate in the presence of the 
MatrigelMatrix. Values represent the mean ± 95% C.I. of 3 independent samples per 
group. The asterisk indicates that the gluc + Matrigel values differ significantly from 
the non-Matrigel gluc control group at p < 0.05. 
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Figure 48.  In vitro effect of Chloroquine on CT-2A cell viability in 
MatrigelMatrix. (A) CT-2A cells were seeded in 24 well plates as described in 
Materials and Methods in the presence or absence of MatrigelMatrix ± 20 μM CQ in 
complete DMEM.  Cell viability was assessed 24 hours later via bioluminescent imaging.  
CT-2A cell viability was unaffected by CQ treatment in complete media. Data are 
expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 3-6 independent samples per group. (B) Reduction in viability in CT-2A cells 
when seeded in 0.8 mM glutamine compared to complete DMEM (comp). Data are 
expressed as the mean percent increase in cell number relative to the 0 hr time point ± 
95% C.I. of 6 independent samples per group.  The asterisks indicate that viability in the 
glutamine group differs significantly from the complete DMEM control group at a p < 
0.01. 
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Figure 49.  In vitro effect of Chloroquine and MatrigelMatrix on CT-2A cell 
viability while under energy stress.  CT-2A cells were seeded in 24 well plates as 
described in Materials and Methods in the presence or absence of MatrigelMatrix ± 20 
μM CQ in 0.8 mM glutamine.  Cell viability was assessed 24 hours later via 
bioluminescent imaging.  CT-2A cell viability was not enhanced by the presence of the 
MatrigelMatrix. Data are expressed as the mean percent increase in cell number 
relative to the 0 hr time point ± 95% C.I. of 6 independent samples per group.  
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Figure 50.  Phagocytic behavior of the VM-M3 cell line.  Phagocytosis was determined 
as described in the Materials and Methods.  Phagocytic behavior was assessed from 
merging (Merge) the fluorescence (GFP) and the differential interference contrast (DIC) 
images.  The non-opsonized fluorescent beads were engulfed (phagocytosed) by the VM-
M3 cells. 
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Figure 51.  Effect of collagen coated latex beads on VM-M3 viability under energy 
stress.  VM-M3 cells were seeded as described in the Materials and Methods in the 
presence of non-coated (LB) or collagen coated (LB + Col) latex beads in 5 mM glucose.  
After 24 hours cell viability was assessed via bioluminescent imaging.  VM-M3 cell 
viability was enhanced in the presence of the collagen coated latex beads.  Data are 
expressed as the mean percent increase in cell number relative to the 0hr time point ± 
95% C.I. of 4 independent samples. The asterisks indicate that viability in the collagen-
coated group differs significantly from the non-coated control group at p < 0.01. 
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Figure 52.  Effect of collagen coated latex beads on VM-M3 lactate and ammonia 
production under energy stress.  VM-M3 cells were seeded as described in Figure 50.  
Media aliquots from each group were taken after 24 hours.  Lactate and ammonia 
accumulation was determined using an appropriate enzymatic assay.  Values represent 
the mean ± 95% C.I. of 3 independent samples per group.   There is no statistically 
significant difference between the two groups for either lactate or ammonia values. 
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Figure 53. Experimental design.  VM mice were implanted with VM-M3/Fluc tumor 
tissue s.c. as described in Materials and Methods. Chloroquine (CQ) administration, with 
or without a 60% calorie restriction (CR), began on day 4-6.  Organs were removed 18-
20 days post implantation and imaged ex vivo.  
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Figure 54.  Effect of Chloroquine on VM-M3/Fluc primary tumor size.  VM mice 
were implanted s.c. with VM-M3/Fluc tumor tissue as described in Materials and 
Methods.  Mice were sacrificed 18-20 days post implantation and the tumor was removed 
and weighed.  Values represent the mean  ± SEM of 6 mice per group.  There is no 
statistically significant difference between the two groups. 
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Figure 55.  Effect of Chloroquine on VM-M3/Fluc tumor metastasis. VM mice were 
implanted s.c. with VM-M3/Fluc tumor tissue as described in Materials and Methods.  
Organs were removed 18-20 days post implantation and imaged ex vivo.  
Bioluminescence values were plotted on a log scale.  Values represent the mean  ± SEM 
of 6 mice per group.  There is no statistically significant difference between the two 
groups. 
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Figure 56.  Effect of Chloroquine and CR on VM-M3/Fluc primary tumor size. VM 
mice were implanted s.c. with VM-M3/Fluc tumor tissue as described in Materials and 
Methods.  Mice were sacrificed 18-20 days post implantation and the tumor was removed 
and weighed.  Values represent the mean  ± SEM of 5-6 mice per group.  There is no 
statistically significant difference between the CR and CR + CQ groups. 
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Figure 57.  Effect of Chloroquine and CR on VM-M3/Fluc tumor metastasis. VM 
mice were implanted s.c. with VM-M3/Fluc tumor tissue as described in Materials and 
Methods.  Organs were removed 18-20 days post implantation and imaged ex vivo.  
Bioluminescence values were plotted on a log scale.  Values represent the mean  ± SEM 
of 5-6 mice per group.  There is no statistically significant difference between the CR and 
CR + CQ groups. 
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Figure 58. Experimental Design.  VM mice were implanted with VM-M3/Fluc tumor 
tissue i.c. as described in Materials and Methods. Chloroquine (CQ) administration, with 
or without a 60% calorie restriction (CR), began on day 4-6.  Brains were removed 12-15 
days post implantation and imaged ex vivo. 
Day 0:
Implant
tumor tissue
into right
cerebral
hemisphere
Day 4-6:
Image
Day 12-15:
Remove
and image
brain ex
vivo
Start CQ
(45 mg/kg/day) ±
60% CR
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Figure 59.  Effect of Chloroquine on VM-M3/Fluc brain tumor growth and 
invasion. VM mice were implanted with VM-M3/Fluc tumor tissue i.c. as described in 
Materials and Methods.  Brains were removed 12-15 days post implantation and 
sectioned down the midline.  Ipsilateral and contralateral hemispheres were imaged ex 
vivo.   Bioluminescence was plotted on a log scale. Values represent the mean  ± SEM of 
4-5 mice per group. There is no statistically significant difference between the two groups 
for either hemisphere. 
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Figure 60.  Effect of Chloroquine and CR on VM-M3/Fluc brain tumor growth and 
invasion. VM mice were implanted with VM-M3/Fluc tumor tissue i.c. as described in 
Materials and Methods.  Brains were removed 12-15 days post implantation and 
sectioned down the midline. Ipsilateral and contralateral hemispheres were imaged ex 
vivo.   Bioluminescence was plotted on a log scale.  Values represent the mean  ± SEM of 
4-7 mice per group.  There is no statistically significant difference between the CR and 
CR + CQ groups for either hemisphere.  The asterisk indicates that the values for the 
contralateral hemisphere from the CR + CQ group differs from the AL control group at a 
p < 0.05. 
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Table 1: Percentage of animals with metastasis to organsa
Group (n) liver lung kidney spleen
AL (24) 100 100 46 63
CR (10) 100 90 50 80
a The presence of metastasis was detected with bioluminescence 
imaging.
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Table 2: Percentage of animals with metastasis to organsa
Group (n) liver lung kidney spleen
control (19) 100 100 47 68
DON  (12) 0 0 0 50
DON + CR (11) 0 0 0 27
a The presence of metastasis was detected with bioluminescence 
imaging.
* The asterisk indicates that the DON or DON + CR group is
significantly less than the control group as calculated by chi square 
analysis at the p<0.01 level.
*
*
*
*
*
**
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Supplemental Figure 1.  Ketone transitioned astrocytes in culture.  Astrocytes were 
transitioned to a low glucose high ketone media as described in the Materials and 
Methods.  Images were taken approximately 30 days after the start of ketone 
transitioning.  Images are taken at 200X. 
+ -OHB - -OHB
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Supplemental Figure 2.  Effect of Phenylbutyrate (PBA) on VM-M3 cell viability in 
vitro. VM-M3/Fluc cells were seeded in DMEM in 24 well plates as described in the 
Materials and Methods and treated with PBA (0-100 mM).  Cells were imaged after 24 
hours using the Xenogen IVIS system.   VM-M3 cell viability was inhibited in a dose 
dependent manner.  Data are expressed as the mean percent increase in cell number 
relative to the non-drug control ± 95% C.I. of 4 independent samples per concentration. 
n = 4
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Supplemental Figure 3.  Schematic representation of metabolic pathways.  Illustrated 
are the glucose and glutamine utilizing metabolic pathways of glycolysis and 
glutaminolysis respectively.  Reactions of the TCA cycle take place in the mitochondrial 
matrix while reactions of the ETC take place in the inner mitochondrial membrane.  
Various metabolic inhibitors and their sites of inhibition are illustrated.  Abbreviations; 3-
NP; 3-Nitropropionic acid; ATP, adenosine tri-phosphate; ETC, electron transport chain, 
FADH2, flavin adenine dinucleotide (reduced form); GTP, guanosine tri-phosphate; 
meso, meso-Tartrate; NADH, nicotinamide adenine dinucleotide (reduced form); Oligo, 
Oligomycin; TCA, tri-carboxylic acid cycle. 
3-NP
Oligomeso
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Supplemental Figure 4.  Proposed mechanism by which glutamine maintains 
viability in the VM-M3 cell line.  Glutamine enters the TCA cycle as -ketoglutarate 
generating energy from substrate level phosphorylation from the conversion of succinyl-
CoA to succinate.  Citrate from the TCA cycle is extruded from the mitochondria to the 
cytosol whereby it is converted to oxaloacetate (OAA) and acetyl-CoA.  Acetyl-CoA is 
further used in fatty acid synthesis.  OAA is converted to malate, which re-enters the 
mitochondria.  Once in the mitochondria, mitochondrial malic enzyme (ME) converts 
malate to pyruvate, which is further converted to acetyl-CoA.  Acetyl-CoA can now re-
enter the TCA to allow for continued TCA cycling. 
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Supplemental Figure 5.  Correlation between ATP concentration, VM-M3 cell 
number and bioluminescence.  ATP (A) and VM-M3 cells (B) were assayed for 
bioluminescence as described in the Materials and Methods.  
AB
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DISCUSSION 
First, I present a novel in vivo model for brain tumor growth and invasion.  Most 
available brain tumor models fall short of fully recapitulating all major characteristics of 
human GBM.  An accurate in vivo model is necessary for the development of therapies 
that can target both local and distant tumor cell invasion.  To date, no xenograft model or 
chemically induced rodent model displays the invasive characteristics of the VM-M3 
model, to include sub-pial and ventricular spread, perivascular, perineuronal, peri- and 
intra-fascicular growth, and inter-hemispheric invasion.  These routes of invasion have 
been referred to as the Secondary Structures of Scherer (Scherer 1938; Rubinstein 1972).  
These structures were identified in highly invasive human brain tumors to include GBM, 
astrocytoma, and oligodendroglioma (Scherer 1938, 1940a).   The secondary structures 
described the growth of invasive tumor cells along the pre-existing structures of the 
nervous system and were independent of histological grade or classification (Scherer 
1938, 1940a). This is important as histological classification of brain tumors can be 
ambiguous at best (Scherer 1940b). 
 
Although the murine GL261 glioma model also displays several invasive qualities of the 
VM-M3 brain tumor model, it does not express ventricular and inter-hemispheric spread 
and the invasive phenotype is limited to the invading edge of the tumor (Zagzag et al. 
2008).  Additional advantages of the VM-M3 model include rapid and consistent growth 
patterns both in vivo and in vitro, a syngeneic host, and low immunogenicity as illustrated 
by robust growth at subcutaneous implantation sites (Huysentruyt et al. 2008; 
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Huysentruyt et al. 2010).  In vitro, the cells express two primary morphologies, which are 
cell cycle dependent.  During division, the cells are small and round, but become flat and 
pancake shaped during the resting state as we previously described (Huysentruyt et al. 
2008; Huysentruyt et al. 2010).  Though the VM-M3 cells predominately display the 
small and round morphology in vivo, additional pleomorphic cells are found throughout 
the tumor consistent with the cellular morphologies seen human GBM (Rubinstein 1972).  
VM-M3 cell growth and morphology is also consistent over multiple passages both in 
vivo and in vitro.  The VM-M3 model is therefore unique in its ability to fully replicate 
the growth and invasive patterns of human GBM.  
 
In addition to the similarities in growth, cell morphology, and invasion, the VM-M3 
tumor also had genetic similarities with human GBM.  Along with CXCR4 and Ki-67, a 
number of genetic markers have been linked to the invasive and aggressive phenotype of 
human GBM (Hoelzinger et al. 2005; Li et al. 2009).  Interestingly, insulin-like growth 
factor binding protein 2 (IGFBP-2) is known to be upregulated in human GBM (Fuller et 
al. 1999; Rickman et al. 2001).  However, a more specific analysis revealed that IGFPB-2 
is highly expressed in the cells of the tumor core, but is significantly down regulated in 
the cells along the invasive edge, suggesting that there is a distinct molecular signature in 
the invasive versus non-invasive cells within the same tumor (Hoelzinger et al. 2005).  I 
showed that the IGFBP-2 gene was highly expressed in the cells of the VM-NM1 tumor, 
which grows more rapidly but is less invasive than the VM-M3 tumor (Huysentruyt et al. 
2008).   Our findings are consistent with those of a previous study showing IGFBP-2 
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expression in the core tumor cells of a GBM (Hoelzinger et al. 2005).  However, 
expression of IGFBP-2 was low in the VM-M3 invasive tumor cells, consistent with the 
expression profile of the invasive rim of human GBM (Hoelzinger et al. 2005). 
 
The VM-M3 tumor is labeled with the firefly luciferase gene allowing for non-invasive 
detection of tumor growth and invasion via bioluminescent imaging.  Bioluminescent 
imaging has been established as an accurate tool for measuring tumor growth over time 
(Deroose et al. 2006; Szentirmai et al. 2006; Maes et al. 2008).  As the VM-M3 tumor 
cells are invasive to all brain regions, I developed a novel bioluminescent-based 
quantitative assay for evaluating the extent of tumor invasion into the cortex, 
hippocampus, brain stem, and cerebellum. I showed that bioluminescence could be 
correlated with histological data on tumor growth and invasion.  In contrast to histology, 
bioluminescent imaging is a more accurate measure of distal tumor cell invasion to 
multiple brain regions. This feature will allow for the quantitative assessment of potential 
therapies that target brain tumor invasion. 
 
Calorie restriction has not been evaluated as an anti-invasive brain cancer therapy due to 
the lack of an invasive brain tumor model.  I show that calorie restriction, which 
significantly reduces tumor growth and angiogenesis in the non-invasive murine CT-2A, 
EPEN, and human U87 experimental models (Mukherjee et al. 2002; Mukherjee et al. 
2004; Zhou et al. 2007), is also capable of reducing tumor growth and invasion of our 
highly invasive VM-M3 tumor model.  Studies in humans have since linked high 
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circulating glucose levels with a poor prognosis in patients diagnosed with GBM (McGirt 
et al. 2008; Derr et al. 2009).  Additionally, a restricted ketogenic diet has been 
introduced into the clinical setting with positive results (Nebeling et al. 1995).  Because 
most brain tumors are highly glycolytic, they rely heavily on glucose as a major energy 
source (Warburg 1956; Seyfried and Mukherjee 2005).  Calorie restriction lowers 
circulating plasma glucose and targets those pathways associated with tumor glycolysis 
(Seyfried et al. 2003; Seyfried and Mukherjee 2005; Marsh et al. 2008b).  In addition to 
reducing glucose, calorie restriction also elevates circulating ketone bodies that are 
metabolized by normal brain tissue (Seyfried and Mukherjee 2005; Zhou et al. 2007).  
Ketone body metabolism takes place in the mitochondria and provides non-glucose 
derived reducing equivalents for oxidative phosphorylation.   The VM-M3 cell line 
however has alterations in both mitochondrial lipid composition and electron transport 
chain enzyme activities, which would compromise normal mitochondrial function 
(Kiebish et al. 2008b).  In addition, the VM-M3 cell line was unable to transition to 
ketones under low glucose conditions in vitro, while normal astrocytes successfully grew 
under low glucose, high ketone conditions (Supplemental Figure 1).  Ketones however 
were not toxic to the VM-M3 cell line in vitro and therefore, the increase in circulating 
ketones did not likely contribute to VM-M3 cell death under CR.  We have also shown 
that a restricted ketogenic diet reduced HIF-1 and IGF-1 gene expression (Marsh et al. 
2008b).  Reductions in these signaling pathways as a result of calorie restriction also 
result in decreases in Akt and mTOR signaling, both of which are involved in tumor cell 
growth and metabolism (Marsh et al. 2008b; Moore et al. 2008).  Here I show that calorie 
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restriction also significantly reduced the percentage of Ki-67 (+) tumor cells, an indicator 
of cell proliferation (Li et al. 2009).  High Ki-67 expression has been shown to be a 
negative prognostic factor for patients with Glioblastoma multiforme (Persson and 
Englund 2008; Li et al. 2009).  This suggests that the anti-invasive properties of CR are 
due in part to a reduction of proliferative, glycolytic and angiogenic factors.  Additional 
experiments are required to test this hypothesis in the VM-M3 brain tumor model. 
 
Calorie restriction significantly reduced tumor invasion into the contralateral hemisphere 
but did not completely inhibit all invasion.  It has been previously shown that a restricted 
ketogenic diet used in combination with low dose 2-deoxy-D-glucose (2DG), a potent 
glycolysis inhibitor, achieved synergy with regard to reductions in tumor size (Marsh et 
al. 2008a).  We therefore consider that calorie restriction or restricted ketogenic diets can 
be used in conjunction with low dose chemotherapeutic agents to reduce overall toxicity. 
 
I also provide evidence of an increased dependence on glutamine for energy and survival 
in the VM-M3 brain tumor cell line.  It is known that rapidly dividing cells and tumor 
cells are heavily dependent on glutamine for macromolecular synthesis and anaplerosis 
(McKeehan 1982; Kovacevic and McGivan 1983; Newsholme et al. 1985; Newsholme et 
al. 2003b; Deberardinis et al. 2008).  However, few have suggested a potential role for 
glutamine specifically in energy production in the TCA cycle (Reitzer et al. 1979; 
McKeehan 1982; Pisarenko et al. 1985; Weinberg et al. 2000; Schwimmer et al. 2005; 
Phillips et al. 2009).  I suggest that glutamine, as opposed to glucose, is the preferred 
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energy substrate for the invasive and metastatic VM-M3 cell line.  I show that glutamine 
alone is able to maintain a sufficient ATP supply whereas glucose is not.  
Bioluminescence can be directly correlated to ATP concentration (Supplemental Figure 
5A).  In addition, because we use a clonally selected cell population, the amount of 
bioluminescence emitted per cell is standardized, and therefore we can also directly 
correlate bioluminescence with cell number (Supplemental Figure 5B).  Reitzer et al. 
provided evidence that glutamine was the primary fuel used by HeLa cells, and glucose 
was used to generate intermediates for biosynthetic reactions (Reitzer et al. 1979). These 
findings are in opposition to the idea that glutamine derived malate is converted to 
pyruvate in order to generate reducing equivalents for macromolecular synthetic and 
anaplerotic reactions (Newsholme et al. 2003b; DeBerardinis et al. 2007; DeBerardinis 
2008).  In this model, NADPH is generated by the conversion of malate to pyruvate via 
cytosolic malic enzyme.  As a result, pyruvate, derived from glutamine metabolism, is 
thought to be primarily converted to lactate or alanine (Supplemental Figure 3) 
(DeBerardinis et al. 2007; DeBerardinis 2008; Vander Heiden et al. 2009).  However, I 
show that in a glutamine only media, the VM-M3 cells produce very little lactate, which 
is in agreement with the findings of Reitzer et al. (Reitzer et al. 1979).  I also show that 
the inhibition of malic enzyme with meso-Tartrate reduced lactate production in the 
presence of glucose and glutamine, but had no effect on VM-M3 survival or lactate 
production in a glutamine only media.  Interestingly, there are multiple isoforms of malic 
enzyme, two of which are mitochondrial and one is cytosolic (Moreadith and Lehninger 
1984; Teller et al. 1992; Pongratz et al. 2007).  Additionally, the inhibition of malic 
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enzyme via meso-Tartrate also stimulates the reaction in the reverse direction (Do 
Nascimento et al. 1975).   By stimulating the conversion of pyruvate to malate in the 
cytosol, glycolytic flux through lactate dehydrogenase would be reduced.  This could 
explain the reduction in viability and lactate production when the VM-M3 cells are 
incubated with meso-Tartrate only in the presence of glucose.  This perhaps indicates that 
meso-Tartrate is active against cytosolic malic enzyme and not against mitochondrial 
malic enzyme or that the inhibitor is not transported into the mitochondria.  I therefore 
posited that glutamine usage in the VM-M3 cell line is independent of cytosolic malic 
enzyme, and not primarily used for macromolecular synthesis or anaplerosis.  Because 
meso-Tartrate is an analog of malate (Do Nascimento et al. 1975), it seems unlikely that 
the inhibitor would have additional non-specific effects in the cytoplasm.  However, 
specific enzyme assays would be necessary to fully determine the inhibitory effects of 
meso-Tartrate on malic enzyme and on other enzymes involved in glutamine metabolism 
within the mitochondria, as meso-Tartrate has been shown to also inhibit malate 
dehydrogenase and fumarase (Do Nascimento et al. 1975).  
 
Instead of the hypothesis that glutamine derived malate exits the TCA and mitochondria, 
I suggest that glutamine derived TCA citrate is responsible for the generation of 
extramitochondrial malate as previously suggested (Supplemental Figure 4) (Sauer and 
Dauchy 1978; Moreadith and Lehninger 1984).  Malate from the cytoplasm can re-enter 
the mitochondria where mitochondrial malic enzyme can then convert malate to pyruvate.  
This would generate a separate mitochondrial pool of pyruvate (Sauer and Dauchy 1978; 
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McKeehan 1982; Kovacevic and McGivan 1983; Moreadith and Lehninger 1984; 
Baggetto 1992; Board and Newsholme 1996).  In a glutamine only media, this allows for 
the regeneration of acetyl-CoA for continued carbon cycling around the TCA (Pongratz 
et al. 2007).  In support of this, Reitzer et al. found that in a glutamine only media, no 
TCA cycle intermediates were depleted with the exception of isocitrate, which is 
downstream of citrate (Reitzer et al. 1979).   Preliminary NMR data indicate that citrate is 
being isotopically labeled as a result of added 
13
C glutamine, further supporting the idea 
that malate remains in the TCA cycle (C. Strelko, unpublished data).  Glutamine derived 
malate that exits the TCA can also result in 
13
C labeled pyruvate and subsequently citrate, 
if pyruvate re-enters the mitochondria.  However, it has been shown that little cytosolic 
pyruvate enters the mitochondria, presumably due to very high activities of lactate 
dehydrogenase and pyruvate dehydrogenase kinase, which inhibits the conversion of 
pyruvate to acetyl-CoA via pyruvate dehydrogenase (Reitzer et al. 1979; Feron 2009; 
Jones and Thompson 2009).   
 
In addition, I show that in the presence of the short chain fatty acid, heptanoic acid, 
survival in glutamine is greatly enhanced relative to either metabolite alone, indicating 
that a source of acetyl-CoA is essential for survival and TCA cycling when glutamine is 
present (Kovacevic and McGivan 1983).  Heptanoic acid is a 7-carbon odd chain fatty 
acid resulting in two units of acetyl-CoA and one unit of propionyl CoA (Nelson and Cox 
2005).  Propionyl CoA can subsequently be converted to succinyl-CoA, which will 
increase the amount of substrates entering the TCA upstream of the energy-generating 
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step (Nelson and Cox 2005).  It is interesting that heptanoic acid is unable to maintain a 
similar level of viability as glutamine alone.  However, recent evidence has shown that 
glioma cell lines contain isocitrate dehydrogenase mutations (IDH1 and IDH2), which 
could affect the level of TCA cycle intermediates such as -ketoglutarate (Dang et al. 
2009).  Additionally, if acetyl-CoA were present without glutamine, it would continue to 
cycle with citrate as described above in a potential futile cycle.  Although propionyl-CoA 
can be converted to succinyl-CoA, this requires ATP input, essentially negating the 
production of GTP from the TCA cycle (Nelson and Cox 2005).  Heptanoic acid however 
can enhance survival in glutamine due to the continued entry of glutamine carbons and 
subsequently -ketoglutarate into the TCA cycle.  In the presence of additional sources 
of acetyl-CoA, a portion of the glutamine carbons could potentially be utilized for other 
biosynthetic reactions allowing for cell growth (DeBerardinis et al. 2007; Vander Heiden 
et al. 2009).  Further 
13
C NMR studies are required that would confirm the metabolism of 
both glutamine and fatty acid carbons when combined. 
 
 -hydroxybutyrate, traditionally considered a ketone body, which is also metabolized to 
acetyl-CoA, did not enhance VM-M3 cell survival in a glutamine only media.  The 
enzymes necessary for ketone metabolism are found in strong association with the inner 
mitochondrial membrane, which relies on cardiolipin for structural integrity (Sato et al. 
1995; Kiebish et al. 2008a).  However, as previously stated, the VM-M3 cells have an 
abnormal cardiolipin profile, perhaps negatively affecting the cell’s ability to metabolize 
ketones (Kiebish et al. 2008a).  A number of tumor cell lines have also been found to be 
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deficient in expression or activity of the key enzymes involved in ketone metabolism 
(BDH and SCOT) (Fredericks and Ramsey 1978; Tisdale 1984; Zhou et al. 2007).  
Therefore, further studies are necessary to determine if the VM-M3 cells express 
abnormal levels of BDH and SCOT or if enzyme activity is impaired.  Additionally, 
SCOT enzyme activity is dependent on succinyl-CoA, and could potentially compete 
with succinyl-CoA synthetase, the energy generating enzyme of the TCA (Phillips et al. 
2009).  Interestingly, we did see a slight but significant reduction in cell viability when 
the VM-M3 cells were incubated in glutamine in the presence of -OHB.  This suggests 
that high ketone levels could inhibit VM-M3 cell growth and survival. 
 
In addition, the inhibition of succinate dehydrogenase with 3-nitropropionic acid (3-NP) 
(Supplemental Figure 3) resulted in a significant reduction in cell survival relative to the 
non-drug control when glutamine was present in the media either as the sole energy 
substrate or in the presence of glucose.  However, cell survival in a glucose only media 
was nearly the same in the presence or absence of the TCA cycle inhibitor.  This 
indicates that the inhibitory action of 3NP is specific to the TCA cycle and glutamine 
metabolism as has been previously illustrated due to its structural similarity with 
succinate (Scallet et al. 2003; Huang et al. 2006).  Because, as previously illustrated, 
bioluminescence imaging can be directly correlated to ATP concentration (Supplemental 
Figure 5A), I suggest that in a glutamine only media, the majority of ATP comes from 
substrate level phosphorylation in the TCA cycle.  However, due to the fact that the 
succinate dehydrogenase complex is also part of the electron transport chain, strict 
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inhibition of the TCA cannot be assumed.  3-NP would also inhibit electron transfer from 
FADH2 to complex II, which could also have an inhibitory effect on glutamine 
metabolism due to a reduction in reducing equivalents.   Because 3-NP resulted in 
significant reductions in cell viability in all conditions tested, though not to the same 
extent, it is possible that at the concentration used, reductions in cell viability could be 
due to non-specific toxicities.  It is unclear if the VM-M3 cells become more vulnerable 
to inhibition when incubated in glutamine compared to glucose.  It would be interesting 
to test a non-metabolic inhibitor in the various metabolites to determine if the metabolite 
present significantly effects drug toxicity. 
 
Interestingly, the inhibition of adenylate kinases by diamino pentaphosphate (Ap5A) 
significantly reduced VM-M3 cell viability when in a glutamine only media but had no 
effect on VM-M3 cell viability when in both glucose + glutamine or glucose alone.  The 
adenylate kinases serve a variety of functions to include phosphate transfer between ADP 
and ATP (Dzeja et al. 2002).  In addition, the adenylate kinases have also been shown to 
be important in the transfer of ATP out of the mitochondria (Janssen et al. 2000; Dzeja et 
al. 2002; Dzeja and Terzic 2003).  Also, these enzymes have been shown to participate in 
the transfer of phosphates from GTP to ATP (Dzeja et al. 2002).  Energy from substrate 
level phosphorylation in the TCA primarily produces GTP (Kibbey et al. 2007; Phillips et 
al. 2009), requiring a phosphate transfer to ATP.  Inhibition of these kinases with Ap5A 
would therefore inhibit both phosphate transfer from GTP to ATP and subsequent 
transfer of the mitochondrial ATP to the cytosol, if the majority of energy were generated 
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from substrate level phosphorylation in the TCA.  Additionally, the addition of 
13
C 
labeled glutamine in culture resulted in 
13
C labeled succinate, further confirming that 
glutamine carbons are entering a highly active TCA (C. Strelko, unpublished data). 
13
C 
NMR studies in the presence of the various metabolic inhibitors could further illustrate 
the pathways utilized by glutamine and the specificity of the selected inhibitors, as many 
inhibitors can become toxic via non-specific mechanisms at high concentrations.  
Another thing to consider is that at low concentrations the impact of the inhibitor may be 
diminished, potentially masking important differences between the response of the VM-
M3 cells in the various metabolites.  Therefore, additional studies using a range of 
concentrations could identify an optimal concentration that allows for specific effects to 
be maximized while toxic effects moderated. 
 
Numerous studies suggest that oxidative phosphorylation is functional in tumor cells and 
can therefore be responsible for energy production (Reitzer et al. 1979; Guppy et al. 
2002; Fantin et al. 2006; Feron 2009).   However, in the VM-M3 cells, the continued 
production of ATP in the presence of oligomycin, the F1-ATPase inhibitor (Supplemental 
Figure 3), supports the Warburg hypothesis that there is a mitochondrial impairment 
preventing the generation of energy via oxidative phosphorylation (Warburg 1956).  
Also, as previously stated, we have shown that electron transport chain enzyme activities 
are reduced in the VM-M3 tumor compared to the VM brain, and mitochondrial lipid 
abnormalities could be the cause (Kiebish et al. 2008a).  This further suggests that the 
VM-M3 cells suffer from a mitochondrial impairment and that the majority of ATP is 
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generated from substrate level phosphorylation from both glycolysis and the TCA cycle.  
Further studies utilizing the uncoupler FCCP could support these findings.    
 
ATP from substrate level phosphorylation specifically in the TCA cycle has been 
demonstrated in both heart and kidney cells in hypoxia (Pisarenko et al. 1985; Weinberg 
et al. 2000).  In a hypoxic environment, ATP from oxidative phosphorylation would be 
inhibited.  However, ATP from substrate level phosphorylation in the TCA cycle, as an 
alternative to glycolysis or oxidative phosphorylation, has never before been 
demonstrated in cancer cells.  I therefore have the first evidence of energy generation 
from the TCA in the highly metastatic VM-M3 cell line.   
 
Glutamine is in fact the highest concentrated amino acid in circulation (Darmaun et al. 
1986; Bode 2001; Newsholme et al. 2003a).  My data suggest that the VM-M3 cells are 
capable of generating enough energy from glutamine alone to maintain survival.  Hence, 
this may be why calorie restriction is largely ineffective in reducing metastatic spread.   
Though calorie restriction acts by reducing circulating plasma glucose levels, evidence 
shows that circulating glutamine levels are increased in mice during calorie restriction 
(Selman et al. 2006).  Additionally, plasma glutamine levels have been shown to rise in 
rats implanted with tumors as a result of net release from muscle and liver tissues 
(Quesada et al. 1988; Souba 1993).  I show that only small amounts of glucose in the 
presence of glutamine are necessary to maintain cell growth and survival in vitro.  CR 
however, had some inhibitory effect on the VM-M3 primary tumor grown 
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subcutaneously.  Previous studies have shown CR to be anti-angiogenic and anti-
inflammatory mediated in part by an elevation in ketone levels (Mukherjee et al. 2002; 
Mukherjee et al. 2004; Veech 2004).  Therefore, the anti-angiogenic and anti-
inflammatory action of CR could be responsible for the reduction in primary tumor size.  
As glutamine promotes VM-M3 cell growth and survival, the failure of CR to target 
glutamine levels could be responsible for the failure of CR to inhibit VM-M3 tumor 
metastasis.  
 
The brain however may be more responsive to CR because high plasma levels of 
glutamate, the metabolic product of glutamine, and glutamine itself, are not reflected in 
the brain due to saturation of the transporter in the blood brain barrier (Smith 1991).  
Glutamine can also be synthesized from precursors within the brain.  The concentrations 
of these “dispensable” amino acids are therefore not affected by changes in plasma 
concentrations (Smith 1991).  Within the brain, glutamate is a neurotransmitter and thus 
glutamine/glutamate cycles are under tight control by the surrounding astrocytes (Daikhin 
and Yudkoff 2000).  Therefore, in the brain, the VM-M3 cells may have to rely more on 
glucose availability than glutamine. 
 
In addition, I show that the glutamine analog, 6-diazo-5-oxo-L-norleucine (DON), had a 
significant inhibitory effect on VM-M3 growth in vitro and on VM-M3 tumor growth and 
metastasis in vivo.   Previous reports have suggested that the inhibitory effect of DON 
was due to its inhibition of purine and pyrimidine synthesis (Livingston et al. 1970; 
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Ovejera et al. 1979; Lyons et al. 1990; Griffiths et al. 1993).  However, I am suggesting 
that the principle inhibitory action of DON is through the inhibition of ATP synthesis via 
substrate level phosphorylation in the TCA as a result of reduced glutamine metabolism.  
It has previously been determined that in mouse leukemia cells, DON induced a 
significant reduction of both ATP and GTP (Lyons et al. 1990).  Therefore, it is unclear if 
a reduction in ATP is a cause or effect of reduced purine and pyrimidine synthesis.  
Presently, we know that glutamine is sufficient to maintain VM-M3 cell survival in vitro.  
Because survival is enhanced in both glucose and glutamine, it is possible that glutamine 
stimulates glycolysis in VM-M3 cells as has been previously demonstrated in C6 glioma 
cells (Portais et al. 1996).  As a result, a significant fraction of ATP could be generated 
from glycolysis while glutamine metabolism could be used for nucleotide biosynthesis.  
 
It is interesting to note that although DON inhibited metastasis to the liver, lung, and 
kidneys, DON treatment alone had no effect on metastasis to the spleen.  The spleen has 
been determined to be a large reservoir of monocytes, and may represent a sanctuary for 
the myeloid-like metastatic cells (Swirski et al. 2009).  Interestingly, studies have shown 
increases in glutaminase activity in the spleens of tumor bearing mice (Aledo et al. 1998).  
Glutaminase is the first enzyme involved in glutamine metabolism.  This perhaps 
indicates that the spleen could support tumor growth due to an influx of glutamine 
originally intended to support immune function (Medina 2001).  Further studies are 
required in order to determine the factors involved in tumor cell metastasis to the spleen. 
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We showed that DON administration in vitro primarily resulted in an inhibition of cell 
growth, but was not cytotoxic.  Additionally, in vivo, whole body bioluminescence was 
nearly unchanged over the course of DON treatment with the exception of spleen 
metastasis (data not shown).  This indicates that both in vivo and in vitro, DON is acting 
to inhibit cell growth, consistent with previous reports in human studies (Magill et al. 
1957).   However, there have been reports of tumor regression indicating that DON can 
be useful in both early and late stage tumor management (Magill et al. 1957; Livingston 
et al. 1970). 
 
Because glucose and glutamine acted synergistically in vitro, I developed a diet/drug 
combination that targeted both glucose and glutamine in vivo.  Previous studies have 
found that calorie restriction administered together with low doses of 2-deoxyglucose, an 
inhibitor of glucose metabolism, acted synergistically to reduce brain tumor growth 
(Marsh et al. 2008a).  Previous studies also showed that calorie restriction is a powerful 
anti-angiogenic therapy and an inhibitor of Akt signaling (Mukherjee et al. 2002; 
Mukherjee et al. 2004; Marsh et al. 2008b).   In addition, in vitro, glucose and glutamine 
acted synergistically to promote VM-M3 cell survival and growth.  Therefore, I sought to 
determine if calorie restriction and DON treatment could act synergistically to reduce 
systemic metastasis in vivo.  I show that DON treatment, either alone or in combination 
with CR, significantly reduced tumor growth and metastasis. Moreover, less DON was 
used to achieve therapeutic effect in the DON + CR mice than in the mice treated with 
DON alone.  Drug doses for the mice were adjusted in order to reduce potential toxicities 
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or extreme energy stress.  The mice on DON + CR were active throughout the study and 
maintained a healthy body weight.  Interestingly, the mice on DON treatment alone 
showed a more adverse response to drug treatment than did the mice on DON + CR, as 
illustrated by a drop in body weight and lethargy over the last 3 days of the study.   
Toxicity in the mice treated with DON alone became more evident as the study 
progressed.  Toxicity was reduced and survival was enhanced when DON was 
administered together with CR since less drug was needed to achieve therapeutic effect.  
Moreover, the incidence of metastasis to spleen was significantly lower in the DON + CR 
mice than in the mice treated with DON alone.  This implies that both glucose and 
glutamine are major sources of energy for the VM-M3 tumor cell line.  My findings 
should stimulate renewed interest in DON and other glutamine targeting drugs for the 
treatment for human metastatic cancer especially when combined with calorie restriction 
or other drugs that target glucose metabolism. 
 
In addition to DON, phenylbutyrate (PBA) has been used extensively in vitro and in 
human clinical trials (Engelhard et al. 1998; Dyer et al. 2002; Li et al. 2004; Phuphanich 
et al. 2005; Lopez et al. 2007).  In humans, PBA is metabolized to phenylacetate (PA), 
which then covalently conjugates with glutamine (Thibault et al. 1994; Darmaun et al. 
1998).  This PA-glutamine conjugate is then excreted, effectively removing glutamine 
from circulation (Darmaun et al. 1998).  Although current studies utilize PBA as a 
histone deacetylase inhibitor, its mechanism of action could be due in part to a reduction 
of circulating glutamine.  In vitro, PBA displayed a dose dependent toxicity towards the 
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VM-M3 cell line (supplemental Figure 2).  However, studies in vivo could not be 
evaluated in our model because mice metabolize PBA differently than humans.  In the 
mouse, PA primarily conjugates with glycine (James et al. 1972).  Therefore, any 
possible inhibitory action of PBA could not be attributed to an inhibition of glutamine 
metabolism.  Because PBA has already been introduced in clinical trials and is well 
tolerated by humans (Thibault et al. 1994), PBA can potentially be used in place of DON 
as a glutamine-targeting drug.  Because PBA is well tolerated, the toxicities traditionally 
seen with DON treatment could be avoided. 
 
It is interesting to note that the VM-M3 cell line is myeloid-like, displaying genetic, 
morphologic, and behavioral characteristics of macrophages (Huysentruyt et al. 2008).  In 
addition, it is well known that glutamine along with glucose is a major energy substrate 
for cells of myeloid origin (Newsholme et al. 1987; Newsholme et al. 1996).  High rates 
of both glycolysis and glutaminolysis allow for precise regulation of processes that use 
intermediates of these pathways (Newsholme et al. 1985; Newsholme et al. 1987).  
Current hypotheses state that mitochondrial instability leads to genomic instability via the 
retrograde signaling pathway, thus increasing the potential for oncogenic transformation 
(Butow and Avadhani 2004; Erol 2005; Singh et al. 2005).  The retrograde signaling 
pathway consists of a series of sensors that detect mitochondrial instability as a result of 
impaired energy production.  Sensors such as HIF-1 and NfB respond to reactive 
oxygen species and increased intracellular calcium levels, which are indicators of 
mitochondrial damage and an impairment of respiration (Butow and Avadhani 2004). 
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Over time, this respiration impairment would result in the upregulation of TCA and 
glycolytic substrate level phosphorylation, induce the default state of proliferation, and 
induce genetic defects, resulting in cancer (Butow and Avadhani 2004; Soto and 
Sonnenschein 2004; Erol 2005; Singh et al. 2005; Seyfried and Shelton 2010).  The VM-
M3 cell line’s dependence on TCA substrate level phosphorylation for energy, along with 
the cell’s altered mitochondrial lipid profile and reduced ETC enzyme activity suggests 
an impaired respiratory capacity (Kiebish et al. 2008a).  When this respiratory 
impairment occurs in a myeloid cell, the result is a tumor cell that is highly dependent on 
glutamine, and is capable of metastatic spread.  
 
In addition to an increased dependence on glutamine, I also show that the VM-M3 cell 
line is capable of phagocytosis, another property of myeloid cells.  A number of human 
metastatic tumors display similar phagocytic properties, to include, brain, skin, lung, and 
breast (Spivak 1973; Coopman et al. 1998; Ghoneum and Gollapudi 2004; Abodief et al. 
2006; Lugini et al. 2006; Fais 2007; Huysentruyt et al. 2008; Moonda and Fatteh 2009; 
Huysentruyt et al. 2010).  It had been suggested previously that these phagocytic 
capabilities were not for the destruction of host immune cells, but for the generation of 
ATP during times of energy stress (Lugini et al. 2006; Fais 2007).  Because calorie 
restriction was ineffective in reducing metastatic spread I sought to test this phagocytic 
property by developing an in vitro assay utilizing a 3-dimensional matrix of extracellular 
matrix glycoproteins.  I showed that when the VM-M3 cells are in this matrix, survival 
during energy stress is significantly enhanced relative to a non-matrix control.  In 
 195 
addition, I show that there is an increase in lactate, indicating an increase in glycolysis 
when in the presence of this matrix material.  I further tested this hypothesis by adding 
chloroquine, a lysosomal targeting drug.  Chloroquine is a lysotropic compound that 
aggregates in the lysosomes.  As a result, lysosomal pH is increased, rendering digestive 
enzymes inactive (Dang 2008; Maclean et al. 2008).  Therefore, chloroquine would 
render phagocytosed material unavailable for digestion.  It is interesting that cholorquine 
not only inhibited cell survival in the matrix, but also in the absence of the matrix only 
when under energy stress.  This perhaps suggests that these cells are also capable of 
autophagy and/or cannibalism (Fais 2007).  Autophagy or “self eating” is often initiated 
in response to energy stress and serves as a mechanism to derive nutrients from the 
degradation of internal organelles and macromolecules (Jones and Thompson 2009).  
Therefore, chloroquine could act as a broad inhibitor of autophagy, cannibalism, and 
phagocytosis. 
 
I also developed an additional assay to test whether or not the VM-M3 cells were capable 
of generating energy from the digestion of phagocytosed material.  I coated non-
opsinized latex beads with the most common matrix protein, collagen.  Previous studies 
have shown that macrophages are capable of endocytosing extracellular proteins to be 
digested into individual amino acids, which can alter the rate of extracellular glutamine 
utilization (Newsholme et al. 1987).  I show that survival was significantly enhanced in 
the presence of the collagen coated latex beads compared to the naked beads.  This 
survival however was not accompanied by an increase in lactate due to the fact that 
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collagen does not contain any carbohydrate groups.  However, the ammonia 
concentration was also not significantly higher in the presence of the coated latex beads.  
This may be due to the fact that collagen has a very high glycine content.   In addition, 
the expected small increases in ammonia could have been below the detection limits of 
the assay. 
 
I next hypothesized that under calorie restriction, the phagocytic behavior of the VM-M3 
cells could be responsible for their continued survival and metastasis in vivo.  I therefore 
sought to determine if chloroquine would be able to reduce tumor growth and metastasis 
in both the VM-M3 brain tumor model and the VM-M3 model for systemic metastatic 
cancer.   As expected, chloroquine alone had no inhibitory effect on tumor growth, 
invasion, or metastasis.  Unfortunately, chloroquine in conjunction with calorie 
restriction also did not have any effect on tumor growth, invasion, or metastasis.  Calorie 
restriction should induce some level of energy stress on the cells because we know that 
glucose and glutamine work synergistically to allow for cell survival and growth in vitro.  
However, glutamine is a major energy source for the VM-M3 cells, indicating that in 
order to manage tumor growth and metastasis, a unique drug/diet therapy targeting 
glucose, glutamine, and phagocytosis should be developed.   
 
Finally, the myeloid properties of the VM-M3 cells could explain why glutamine is more 
important than glucose as an energy generating fuel.  It has been shown that an elevation 
in glucose uptake results in an elevation of activity in the pentose phosphate pathway 
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(PPP) in macrophages (Newsholme et al. 1996).  The PPP primarily utilizes glucose-6-
phosphate, a glycolytic intermediate, as a precursor.  Therefore, a large majority of 
metabolized glucose may be contributing to the PPP for nucleotide and fatty acid 
synthesis (Jones and Thompson 2009).   The PPP can also generate NADPH required for 
macromolecular synthesis (Tennant et al. 2009).  It had previously been suggested that 
the high rate of glycolysis in tumor cells in the presence of glutamine was for the purpose 
of providing these essential precursors rather than strictly for energy production (Reitzer 
et al. 1979; McKeehan 1982; Mazurek et al. 2005; Christofk et al. 2008; Kroemer and 
Pouyssegur 2008). Though survival in glucose + glutamine was approximately 5-fold 
higher than survival in glucose alone (Figure 26), lactate only increased by a factor of 2.5 
(Figure 27).  Therefore, less lactate per cell was produced when glucose and glutamine 
were present, indicating that glycolytic intermediates may be used primarily for 
macromolecular synthesis via the PPP. 
 
Taken together, these findings illustrate the usefulness of the VM-M3 tumor as a model 
for both human GBM and for systemic metastatic cancer.  In addition I show that the 
invasive/metastatic VM-M3 tumor is highly dependent on glutamine for growth and 
survival specifically as a result of ATP generated from substrate level phosphorylation in 
the TCA cycle.  Interestingly, during energy stress, phagocytosis may also play a role in 
maintaining a sufficient ATP supply for VM-M3 cell survival.    
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CONCLUSIONS 
 
In conclusion, I describe a novel model for brain tumor growth and invasion.  This model 
is unique in its invasive qualities and provides a new tool for evaluating potential 
therapies. To date, no xenograft model or chemically induced rodent model displays the 
invasive characteristics of the VM-M3 model, to include sub-pial and ventricular spread, 
perivascular, perineuronal, peri- and intra-fascicular growth, and inter-hemispheric 
invasion. The VM-M3 tumor cells also express molecular markers linked to highly 
malignant Glioblastoma multiforme (Hoelzinger et al. 2005; Li et al. 2009).  In addition, 
the use of bioluminescent data provides a way to quantitate tumor growth and invasion.  I 
also show that calorie restriction, which lowers circulating glucose and elevates ketones, 
is anti-invasive in the VM-M3 brain tumor model.   
 
However, I also provide evidence of an increased dependence on glutamine in the VM-
M3 cell line, similar to a number of other cancer cell lines (Reitzer et al. 1979; 
McKeehan 1982; DeBerardinis et al. 2007; Matheson et al. 2007).   Glutamine utilization 
could support biosynthetic and anapleurotic reactions (DeBerardinis et al. 2007; 
Deberardinis et al. 2008).  However, I have the first evidence in cancer cells that energy 
derived from glutamine is primarily a result of substrate level phosphorylation in the 
TCA cycle.  Due to the myeloid properties of this cell line and of many other human 
metastatic cancers, (Spivak 1973; Ghoneum and Gollapudi 2004; Abodief et al. 2006; 
Lugini et al. 2006; Fais 2007; Huysentruyt et al. 2008; Moonda and Fatteh 2009; 
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Huysentruyt et al. 2010), I suggest that many metastatic cancers possess a higher 
dependence for glutamine rather than for glucose.  In support of this, I show that calorie 
restriction was unable to inhibit tumor metastasis in the VM-M3 model for systemic 
metastasis.  This could be a result of the high levels of glutamine found in circulation 
(Darmaun et al. 1986; Bode 2001; Newsholme et al. 2003a).  The glutamine analog, 
DON, along with calorie restriction significantly reduced both tumor growth and 
metastasis indicating that metastatic cancer can be targeted with metabolic therapies.   
 
In addition, the phagocytic properties of these myeloid-like tumor cells may also serve as 
a mechanism to provide metabolites during times of low nutrient supply (Fais 2007).   
This may occur via phagocytosis and digestion of extracellular material, host cells, 
internal organelles or even other tumor cells (Lugini et al. 2006; Fais 2007; Jones and 
Thompson 2009).  Therefore, I suggest that a unique therapy should be designed that 
targets both the glutamine dependence of the VM-M3 cells as well as their phagocytic 
capabilities.  Due to the similarities between VM-M3 tumor cell behavior and human 
metastatic cancer, the treatment of metastasis may involve similar targets.  
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